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The aging process is strongly associated with decreased activity in the immune
system. Dysregulation of T-lymphocyte function, such as reduced proliferation, is one
problem faced by most elder people, which prevents them from successfully dealing with
exogenous pathogens. Effective regulation of T-lymphocyte activity depends on the
proper and prompt transduction of both positive and negative signals within T-
lymphocytes and reflects the balance between positive and negative effects. Decline of
positive signaling in aging has been studied and reported, while mechanisms concerning
up-regulation of negative signaling with age and its role in immune senescence are still
unclear.
Cbl-b, an E3 ubiquitin ligase, was studied by our lab since it regulates the
ubiquitin process, a protein modification process that has suppressive effects on signaling
pathways. We first determined the reaction of Cbl-b to different stimuli in young rat
splenic T-lymphocytes, and showed that there is a decrease in Cbl-b protein expression
vii
upon CD28 stimulation and such protein degradation is proteasome-dependent only.
We also showed the mechanism of Cbl-b expression regulation involves the intracellular
movement of Nedd4 toward Cbl-b and an up-regulation of Nedd4 expression. Then we
proved that in old splenic T-lymphocytes, decreased proteasome activity was unable to
down-regulate the Cbl-b protein. High levels of Cbl-b in old T-lymphocytes are
functional in preventing PI3K activity and are associated with reduced T-lymphocyte
proliferation upon regular stimulation.
T-lymphocytes from old Cbl-b knock-out mice show similar proliferative reaction
to CD3 stimulation as T-lymphocytes from young wild-type, which establishes the cause-
effect relationship between sustained Cbl-b expression and decreased T-lymphocyte
proliferation. In summary, these data suggest a unique role of Cbl-b in regulating T-
lymphocyte signal transduction and provide critical preliminary data for extending Cbl-b
studies into other fields, such as carcinogenesis.
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Chapter 1: Review of Literature
1.1 OVERVIEW
Healthcare of aged people is a social problem met by countries all over the world.
One of the biggest challenges needing solved in the aging area is improving immune
function to reduce the incidence of age-related diseases in the elderly. Characteristics of
immune senescence include decreased proliferation rate in lymphocytes, and increased
auto-antibody secretion by B-lymphocytes [1, 2]. Various theories of aging have been
put forth to explain the cause of aging from different points of view [3]. Some of these
aging theories place emphasis on the immune system, focusing on decline in T cell
development, alterations in lymphocyte homeostasis, and impaired intracellular signaling
pathways.
The network of intracellular [4] signaling pathways is a complicated system
incorporating stimulatory and inhibitory signals by both positive and negative regulation.
Numerous studies have pointed out that activities and expression of receptors,
modulators, and effectors which transduce and amplify activating signals were down-
regulated or mutant with age [5]. At the same time, those proteins that will block the
signal transduction or decrease the signal strength may have similar impact on the onset
of immune senescence. Phosphorylation is probably one of the most popular
posttranslational modifications of protein that help to “turn on” the signaling network.
Similarly, the role of ubiquitination, another protein posttranslational modification
process, in “turning off” the signaling network could be as important as phosphorylation
in the whole signal transduction world. E3 ubiquitin ligases not only control the rate-
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limiting step in the ubiquitination procedure, but also determine the substrate specificity.
Thus, we want to test the relationship between Cbl-b, an E3 ubiquitin ligase and T cell
activation. Also, we would like to see whether there is any functional and expressional
change to Cbl-b in aged T-lymphocytes as well as the potential mechanisms. Finally,
we want to confirm the role of Cbl-b in aged T-lymphocyte function regulation via an old
Cbl-b knock-out model.
The ultimate goal of this study is to prove that changes in the
ubiquitin/proteasome system during aging may affect the function of T-lymphocytes. A
thorough study on this topic would provide a new mechanism of dysregulation in aged T-




The objectives of the project are:
1) To characterize changes of Cbl-b expression in young stimulated T-lymphocytes
Hypothesis: Stimulation of young T-lymphocytes down-regulate Cbl-b
activity
2) To determine the age-dependent change of Cbl-b in old stimulated T-lymphocytes
Hypothesis: Cbl-b can not be down-regulated in old T-lymphocytes, and are
associated with low proliferation of old T-lymphocyte
3) To establish a cause-effect relationship between Cbl-b activity and T-lymphocyte
proliferation




Cellular Aging and Associated Theories
Nowadays, the concept of “cellular aging” is more extended than originally put
forward. It includes the features of cessation of cell dividing after certain rounds of
doubling [6, 7], accumulation of deteriorative molecules within the cell [8], losing control
to maintain cell homeostasis [9] and altered regulation of gene expression [10]. Since
many common phenotypes of aging such as osteoporosis [11] and inadequate responses
of T cells to viruses [12] are due to the features associated with the cellular aging, the in
vitro cell aging has been correlated with in vivo aging and studies on this topic have
raised several theories about aging.
Telomere Theory of Aging
The telomere is a region located at the terminal end of the linear chromosome. It
is composed of thousands of repeats of TTAGGG in vertebrates. At the time of cell
division, DNA replication can not reach the very end of the chromosome. Instead, each
round of DNA replication will result in the loss of 40-100 bps of telomere at the tip of the
chromosome. Thus, the higher the cell replicative cycle number, the shorter the
telomere length, until it reaches a critical value. After that, cells will stay in an arrested
state in which they stop replicating themselves even when outside stimuli are strong
enough to trigger their division. The observations that the telomere length in fibroblasts
and blood cells from aged donor are statistically shorter [13, 14], patients of Hutchinson-
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Gilford progeria and Werner's syndrome, diseases caused by a defective telomere system,
show symptoms of accelerated aging [15] and shorter telomeres are associated with lower
survival rate in people over 60 years old when facing heart disease and infectious disease
[16] all support the idea that the telomere works as an internal cell division counter that
monitors the “age” of somatic cells and puts “aged” cells into non-dividing state and
eventually determines the overall aging state of the whole body.
Telomere can be extended by a specialized reverse transcriptase, telomerase.
However, the expression of TERT (telomerase reverse transcriptase, the core catalytic
subunit of telomerase) is suppressed in normal somatic cells and is only detectable in
germline cells. The hypothesis that stopping the shortening of the telomere can slow or
reverse the aging process was proved by Wright, Lichtsterner and their team [17].
However, the value of the telomere theory is decreased by other concerns. Some
animals, like mice, have a high telomerase activity and can retain the telomere length
with aging [18]. Also, there is no correlation between the telomere length and the life
span within different stains of mice [19]. Even in human cases, increased telomerase
activity on one hand can immortalized the cells, but on other hand may put the cells
under the threaten of tumor formation, which probably has a more negative impact on
human life span than aging itself [20]. Thus, the function of the telomere and
telomerase in human aging may be important, but still not decisive.
Membrane Hypothesis of Aging
The fluidity of the cell membrane is one of the most significant features
influencing the function of the cell membrane—a permeable lipid bilayer embedded with
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proteins [21, 22]. Cell membranes not only mediate molecular transport in and out of
the cell, but also regulate signal transduction from cell surface receptors. Membrane
fluidity and permeability are mainly determined by the content of phospholipid and
cholesterol. With age, composition of membrane lipids will change in many tissues
resulting in an increased ratio of cholesterol/phospholipid, such change has been noted in
rat liver and skeletal muscle [23], in rat liver microsomal and mitochondrial fractions
[24], and in red blood cells [25]. As a consequence, old cell membranes become more
rigid and resting potassium (K+) permeability decreases. In order to maintain the cell
excitability, more K+ must be brought intracellularly [26]. For example, the K+
concentration within rat brain neural cells can be 32% higher at the age of 24 months
compared to 1 month old rats [27]. High concentrations of intracellular ions will lead to
a higher viscosity which directly affects biological enzyme activity including the DNA-
dependent RNA polymerase [28]. This is of great importance since slowing of DNA or
protein synthesis is another hallmark of cellular aging and prompt DNA and protein
formation is critical to cell division.
Formation of the immunological synapse is another cell function affected by
decreased membrane fluidity. The function of the immunological synapse is to “provide
a mechanism for sustained TCR engagement and signaling [29]”. T cell activation is
initiated by the interaction of T cells with antigen presenting cells (APCs). Namely,
major histocompatibility complex—peptide complexes (MHC-peptide) present at the
surface of APCs that are recognized by T cell antigen receptors (TCRs). Shortly after
the cell-cell interaction, a series of signaling transduction reactions will be triggered and
result in various T cell responses including T cell division and cytokine secretion. It has
been noticed that a specialized structure is formed at the T cell-APC interface zone [30].
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This special structure, termed immunological synapse, is generated by the polarization of
cytoskeleton and is characterized by a TCR cluster at central interaction area and an
integrin ring formed at the surrounding zone [31]. In old mice T cells, failure to move
LAT and Vav into the immunological synapse is responsible for the age-dependent
decline of T cell clonal expansion [32]. Similarly, alteration of the immunological
synapse composition with age in memory T cell subsets leads to defects in the T cell
response [33]. Since cell membrane fluidity is a major factor that determines the
immunological synapse formation [34], the observed changes in the immunological
synapse formation and hyporesponsiveness of T cells with age can be explained by the
age-associated decline of membrane fluidity. However, experiments trying to reverse
the membrane lipid composition changes in older populations by using the plasma
membrane cholesterol-depleting agent methyl-β-cyclodexrin (MBCD) did not increase
cell proliferation in old groups [35] or only increased to a very limited degree [36].
Thus, further studies regarding the “membrane hypothesis” in enhancing cell function
and extending human life span are needed.
Free Radical Theory of Aging
ATP, the energy source of all cell functions, is generated in mitochondria by the
phosphorylation of ADP. This reaction is driven by an electrochemical gradient
produced by the mitochondria electron transport chain. A side effect of this process is
that the electron transport chain will leak electrons to oxygen and form superoxide (O2
·-).
Then, O2
·- will convert into more toxic free radical-containing reactive oxygen species
(ROS) by a series of redox reactions. Besides the normal aerobic metabolism, radiation
is another source that will generate ROS. ROS can oxidatively damage all cellular
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macromolecules, like protein [37], DNA [38], and lipid [39]. Oxidative damage is
already present in cells from young animals [40] and increases with age in various
species [41]. The accumulation of oxidative damage contributes to many age-related
declines in body functions including learning, memory, hearing, locomotion,
reproduction and immune response [42] and are responsible for numerous age-related
degenerative diseases like cardiovascular disease, cataracts, brain dysfunction, chronic
infection and cancer [43].
It is believed that the accumulation of oxidative damage with age is caused by the
combination of accelerated ROS production and a compromised damage repair/removal
system, but is not associated with decreased antioxidant defense [44]. Many studies
have been done to find a way to decrease the rate of ROS production and in turn the rate
of aging. It was found that dietary antioxidant supplementation can increase average
life expectancy at birth (ALE-B) by 20-30% in experimental animals, but has little
beneficial effect on maximum life span (MLS) [45]. So far, by decreasing O2 utilization
in metabolism, caloric restriction (CR) is the only way to increase both ALE-B and MLS.
However, to achieve a significant increase in MLS, the level of CR (decrease by 40%)
would be too high to maintain normal life quality [46]. Experiments about the
application of CR in primates are currently ongoing [47] and the results will give more
valuable information about CR in aging study.
Other Theories of Aging
There are many other theories of aging that have been raised and accepted widely.
Some of them are not limited to the cellular level, like the wear-and-tear theory, which
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states that the normal function of our body depends on the proper function of every organ
in the body in order to deal with almost everything we are facing, either beneficial or
harmful. However, just like a machine, the constant use will wear out the organs and
slow down their working efficiency and finally result in the aging process [48]. Another
widely accepted aging theory, the neuroendocrine theory [49], focuses on hormone
secretion, which is all controlled by the hypothalamus. The hypothalamus works in a
feedback mechanism; it detects the body hormone levels and regulates the hormone
release according to the current hormone level. When we become older, the
hypothalamus loses both its sensitivity in hormone level detection and its precision in
hormone secretion regulation. The result of such dysregulation is a dramatically
decreased level of hormones that are important for body function.
It is crucial to realize that these theories are not exclusive to each other. Some
theories are the result of other theories. For example, mitochondria, the energy
producing organelle of every cell, faces the damaging attacks from free radicals and lacks
the necessary defense mechanism to correct them. Thus, when free radicals accumulate
with time, mitochondrial function declines and the free radical theory and the
mitochondrial decline theory are linked together. Some theories of aging are
interlinked, each representing an aspect of a complicated network. For example, the
telomerase theory of aging explains the view of the genetic clock [14]; the error and
repairs theory focuses on the repair machinery [50, 51]; and the redundant DNA theory
concentrates on the ratio of repeated DNA sequences in the genome [52]. Although
focusing on different points of view, one common theory underneath them is the genetic
control theory, which believes that our lifespan and aging process is pre-determined in
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our DNA sequence when we are born. We can speed or slow the aging rate by working
on any one of the aspects listed above.
It is also interesting to notice that some aging theories are specific to the immune
system, like the autoimmune theory, which suggests the immune system begins attacking
itself due to a decline in distinguishing foreign attackers from self-protein [53], and the
thymic-stimulating theory, which states that the shrinkage of the thymus and the decrease
in thymic hormone production with age cause the malfunction of the immune system in
the elderly [54]. Actually, there are multiple changes found in the immune system that
contribute to the aging process and will be illustrated in detail in the next section.
The Aging Immune System
There is a well established association between aging and increased morbidity and
mortality due to infectious diseases [12, 55]. That is why studies in immune senescence
attract so many gerontologists. Humans and rodents show many age-related immune
defects including thymic involution, decreased T-cell response to antigenic stimuli,
altered cytokine expression by T cells and reduced formation of high-affinity antibodies
[12]. Considering that the immune system is a quite complicated network composed of
different cell types with distinct functions, declined immune function accompanied by
aging must be the comprehensive result of deficiency occurring in individual immune
cells at different stages.
Thymic involution and T cell development
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T cell development is a multi-step process that takes place in the bone marrow
(BM) and the thymus. Hematopoietic stem cells (HSC), with the phenotype of Lineagelo
c-kit+ Sca-1+ (LSK) Flt3- and originally located in the BM, are the precursors of all
hematopoietic cells. During the T cell development process, they will leave the BM for
the thymus by circulating in the blood and become the earliest intrathymic T progenitors
(ETPs). Within the thymus, ETPs undergo a series of developmental progress, which
can be defined by the cell surface expression of CD4 and CD8 as double negative (DN),
double positive (DP), and single positive (SP). The DN thymocyte can be further
divided into four sub-stages of differentiation by the expression of CD44 and CD25, that
is, DN1 (CD44+CD25-), DN2 (CD44+CD25+), DN3 (CD44-CD25+), and DN4 (CD44-
CD25-). It is in the DN stage that the precursor cells determine to take either the αβ or
γδ T-lineage, more precisely, the pre-TCR-α is expressed in the DN3 stage and the TCR
β-chain selection happens in the late DN3 and DN4 stage [56]. During the DP stage,
cells also experience positive and negative selection according to whether they can
recognize self-MHC and the affinity of such recognition. Positive and negative
selection can eliminate about 98% of thymocytes in the thymus and are essential for
establishing immunological tolerance.
Age will change the number of HSC within the BM, but the number is increased
in long-lived C57BL/6 mice, but decreased in short-lived DBA/2 mice [57]. Moreover,
the ability of HSCs to replenish themselves decreases with age [58]. Meanwhile, their
ability to generate lymphoid precursors is lower in old animals [59]. Thus, the overall
function of HSC for lymphocyte development declines in old mice [1]. The molecular
mechanism underlying the HSC aging is accumulation of defects in genomic and
mitochondrial DNA caused by ROS [58].
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There is no change in the size of the thymus since six months after birth, while the
weight of the thymus is lower in aged individuals, reflecting the composition change
within the thymus that contains more fat tissue with age [60]. As for the thymic
progenitors within the thymus, total number and proportion of DN1 cells that commit to
the T lineage is reduced in the thymus in old animals [61], probably due to the defects of
inputting BM progenitors. In addition, decreased transcription of RAG1 and RAG2 was
observed in aged mice [62]. Since the function of RAG family proteins is to regulate β-
selection, the defects in RAG expression will lead to retardation of DN3 thymocytes from
going through β-selection and less DP thymocyte production in old thymuses [63].
Currently, no evidence exists to suggest that the differentiation steps in DP and SP
thymocytes, including positive and negative selection, are changed with age [64].
T cell proliferation and signaling pathway
Reduced proliferation of T cells after stimulation in vitro is one of the hallmarks
of aging in humans and rodents [12]. This phenomenon may reflect changes in TCR
expression and downstream components in the signaling pathway. Proper T cell
stimulation and subsequent proliferation requires two extracellular signals. Perturbing
the TCR/CD3 complex generates the first, obligatory, signal. The second signal is
generated from co-stimulatory receptors, like CD28, which are critical for determining
proper T cell activation each time the cell is exposed to antigen. There is little evidence
to suggest decreased density in TCRαβ chains or CD3 complex expression with age
[65]. As for the expression of CD28, it is well acknowledged that the percentage of
CD28-positive cells is significantly lower in T cells from old compared to young mice,
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which may help to explain the reduced T-lymphocyte proliferation in aged individuals
[66-68]. However, recent research has shown that not all aged T-lymphocytes are
characterized by the lack of CD28 expression [69, 70]. The progressive decline in
CD28 expression is more closely linked to age-related diseases as opposed to aging itself
[71].
Once the antigenic peptides presented by APCs are bound to the TCR/CD3
complex, a cascade of signaling events will be initiated. Immunological synapses are
first formed at the sites where APCs and T cells are contacted, the declined formation of
immunological synapses with age has been discussed in the previous section “Membrane
Hypothesis of Aging” on page 5. TCR associated protein tyrosine kinases (PTK), like
Lck and Fyn are then activated. Activated PTKs can phosphorylate the immunoreceptor
tyrosine-based activation motifs (ITAMs) of the CD3ζ chain, which leads to the binding
of Zap-70 to phosphorylated ITAMs. Zap-70 is further phosphorylated and activated
and plays a key role in stimulating more enzymes and protein effectors, like
phospholipase C (PLC), LAT, Vav, and Ras. The function of PLC is to hydrolyse the
membrane phosphatidylinositol phosphates (PIP2) and release inositol triphosphate (IP3)
and diacylglyceral (DAG). IP3 can regulate the intracellular Ca
2+ concentration by
opening the Ca2+ channels on the endoplasmic reticulum (ER), and DAG is the second
messenger that activates protein kinase C (PKC). Both the intracellular Ca2+ movement
and PKC activity are essential to the activation of other protein kinases and finally leads
to cell proliferation and IL-2 secretion. Meanwhile, the 3-position hydroxyl group of
the inositol ring of PIP2 is phosphorylated by phosphoinositide 3-kinase (PI3K). The
product, PI(3,4,5)P3, helps to activate protein kinase B (PKB or Akt). This “PI3K/Akt”
signaling pathway is important in oncogenesis since it can regulate various cellular
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processes including cycle progression, cell growth and apoptosis. Amplified expression
of the p110α catalytic subunit of PI3K and Akt are found in human cancers [72]. Also,
in malignant tumors, the PI3K/Akt pathway remain activated due to the function-loss
mutation of PTEN, an antagonist of PI3K [72].
Studies show that enzymatic activity of Fyn is reduced in T cells from both old
humans [73] and mice [74]. With advanced age, function of Lck is declined as well,
because of less association with TCR and less phosphorylation [75, 76]. These
alterations found in the elderly contribute to the age-related impairment of Zap-70
activity, although the expression of Zap-70 and its association with CD3ζ chain is normal
with age [77, 78]. As a result of decreased Zap-70 activation, PLC activity and IP3,
DAG generation are impaired [79]. Reduced Ca2+ flow in old T cells results in the
decreased NF-AT activity whose function is to induce the transcription of genes
responsible for cell-cell interaction and is important to T cells’ proliferation and
differentiation [80]. Low DAG formation leads to less PKC activation and decreased
NF-κB pathway function [81] which is critical for inflammation, autoimmune response,
cell proliferation, and apoptosis [82]. PKC activity can be inhibited by ceramide.
Ceramide accumulates in old cells and contribute to cellular senescence [83]. An age-
associated decrease in the PI3K/Akt pathway is observed in pancreatic acinar cells [84],
indicating that it may be affected in old T cells too.
It is expected that other signaling pathways controlled by activation of Lck/Fyn
will show age-related deficiency also. Studies have found that MAPK activity [85] and
JNK activity [86] decrease in old human T cells. The deficiency in MAPK can be
partially reversed by adding phorbol ester and calcium ionophore [85]. All the data
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together suggest that changes within the early response events after TCR/CD3
engagement are the main reasons for improper T cell signal transduction with age.
Homeostasis and age-associated defect in T cell subsets
According to different definitions, T cells can be classified into different, but
sometimes, overlapping subsets. Based on the expression of surface markers, T cells
can be divided into CD4+ T cells and CD8+ T cells. According to their function, T cells
will be grouped into helper T cells and cytotoxic T cells. All T helper cells express
CD4 on the surface and most of the cytotoxic T cells express CD8. There also exists a
small portion of cytotoxic T cells with CD4 expression [87]. CD4+ T helper cells can be
further subdivided into T helper 1 (TH1) and T helper 2 (TH2) cells according to their
cytokine secretion and function. Both the CD4+ and CD8+ T cells can be divided into
naïve and memory T cells depending on whether they have been recognized and activated
by the antigen. Each T cell subset has its unique function within the T cell response to
infection. The composition of T cell subsets, as well as the function of individual
subsets, will change with advanced age.
In young animals, homeostasis of T cell subsets is established so that the number
of recent thymic immigrants and the number of naïve T cells lost each day is nearly
equal. However, with age, the thymic output of naïve T cells decreases while the
persistent exposure of individuals to acute and chronic pathogens drive more naïve T
cells into memory cells. Thus, the proportion of memory T cells in both CD4+ and CD8+
T cells is elevated [88, 89]. Another age-associated feature of T cell subsets is
decreased CD4+ T cells in aged human PBLs (peripheral blood lymphocyte), resulting in
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an increased CD4/CD8 ratio with age [90]. CD4+ and CD8+ T cells also express
significantly more P-plycoprotein with age [91].
Based on these observations, an “immune subset factor” is calculated based on the
level of CD4+, CD8+, CD4 memory (CD4M), CD8M, CD4 naïve, CD4 with P-
glycoprotein expression (CD4P), and CD8P. This factor has a higher score when there
are higher levels of CD8, CD4M, CD8M, CD4P and at the same time, lower levels of
CD4, CD4 naïve population. The score (termed “F1_18” for mice at the age of 18
months) is a good predictor of lifespan or mortality risk [92].
On one side, the change in T cell subset composition with age will further
influence the function of the whole T cell population, while on the other side, such
compositional changes could also be the result of, or at least reflect, functional alterations
in some T cell subsets.
Although CD4+ T helper cells do not directly take part in immune protection, their
function is indispensable for both humoral and cellular immunity. The major functional
defect of CD4+ T cells found in aging happens in naïve CD4+ T cells. Less CD154
(CD40L) are expressed on aged CD4+ T cells, leading to decreased migratory ability.
As a result, the cognate helper function of aged naïve CD4+ T cell declines and humoral
immunity becomes defective [93]. This functional defect of naïve CD4+ T cell is related
to its post-thymic age, since the newly produced CD4+ T cells from old mice are normal
in their function when compared with those generated in young mice [94].
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The function of the memory CD4+ T cell also depends on the post-thymic age of
the naïve CD4+ T cell when it is activated and differentiates into memory cells. If the
memory T cells were generated at a young age, then those T cells would maintain a
normal function even when the animals become old. Those LCMV-specific memory
CD4+ T cells secrete the same, or ever higher amounts of IFN-γ at 206 days after
infection as 45 days after infection [95]. Newly generated memory CD4+ T cells in
young and old donors showed no difference in persistence, but they did show functional
difference that the aged memory CD4+ T cell population having low proliferation and
cytokine production in vitro and impaired proliferation and cognate helper activity in vivo
[96, 97]. So, in the CD4+ T cell subset, it is the naïve cells that are more vulnerable to
aging.
In the aging process, CD8+ T cells share some features with CD4+ T cells. For
example, the age-related defects, like poor recall response and low production of IFN-γ,
are observed only when the naïve CD8+ T cells are old [95, 98]. Aged CD8+ T cells also
have their own characteristics. Phenotypically, most (>90%) senescent CD8+ T cells
lack the CD28 expression on the surface, which does not happen in old CD4+ T cells [99].
These CD8+CD28- T cells are CD57 positive [100]. Since CD28 is essential for a
variety of critical T cell functions, this phenomenon imparts profound functional changes
associated with this particular subset of CD8+ T cells. Consistent with that, the
CD8+CD28- cells are resistant to apoptosis under various stimuli [101]. Besides this, it
is demonstrated that when under the same stimulatory condition at the fourth round,
CD8+ T cells lose the expression of CD28 as well as the ability to upregulate telomerase
activity while CD4+ T cells continue to show both CD28 expression and telomerase
activity [99]. The CD8+CD28- T cells are incapable of proliferating, and thus, show
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reduced anti-viral suppressive functions. Other important functional changes associated
with CD8+CD28- T cells include the decreased binding affinity between T cells and
endothelial cells, and the subsequent change in T cells moving around within the body
[102]. In vitro culture of CD8+CD28- T cells secrete more IL-6 and TNF-α, this is
consistent with the pro-inflammatory status observed in many aged individuals [103].
Another unique feature associated with old CD8+ T cells is the mono- or
oligoclonal expansion (TCE). The expanded subset can occupy >80% of all CD8+ T
cells [104, 105]. How TCE are formed is still unclear. Some studies show that they
are the result of continuous exposure to antigen [106, 107]. While others think their
formation is under the control of cytokines [96, 108]. The existence of CD8+ TCE
reduces the diversity of CD8+ T cells and contributes to the immunodeficiency shown in
aged CD8+ T cells [105].
Antibody production and B cell
Humoral immunity is an immune defense system mediated by antibody
production. During old age, both humans and mice experience declines in humoral
immunity, displaying retarded reaction to vaccine/foreign antigen and increased secretion
of auto-antibodies [109]. Although the B-cell-derived plasma cell is the only source of
antibody production within the body, most of its activation is regulated by the T helper
(TH) cell. Thus, humoral immunity aging can be partially explained by the diminished
TH cell function and increased T-cell-mediated suppression with age. However, intrinsic
alterations of B cells must not be neglected from the aging studies.
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The overall number of peripheral B cells does not change with age [110].
However, the subpopulations of B cells do change with age, leading to an increased
proportion of marginal zone (MZ) B cells and “B1” B cells, but decreased proportions of
follicular B cells [111]. Such an alteration in the composition of B cell subsets
contributes to changes in the B cell receptor (BCR) repertoire during old age and
eventually results in the immunoglobulin class of antibodies switching with age from IgG
to IgM [112].
Other studies also showed that changes observed in old peripheral B cells are
actually associated with the age-related decline of B lymphopoiesis within the BM. In
the BM, B lympopoiesis undergoes sequential differentiation as early B-lineage
precursors/common lymphoid progenitors (EBP/CLP), pro-B cells, early pre-B cells, late
pre-B cells and immature B cells [113]. Aging affects B cell development at stages as
early as EBP/CLPs and pro-B cells, [114] which decrease with age. One reason is that
the frequency of AA4.1+ pro-B cells declines with age because the AA4.1+ B cell
expresses high levels of RAG protein and can proliferate rapidly upon IL-7 stimulation
[114]. Besides this, expression of surrogate light chain λ5 reduces with age in pro-B
cells. λ5 protein is a component of pre-B-cell receptors (pre-BCR). As a result, pre-
BCR formation is impaired and pro-B to pre-B cell transition is blocked in senescence
[115, 116]. In addition, pre-BCR can induce the expression of BCL-XL protein, whose
function is anti-apoptosis. Thus, only the pre-B cell with functional pre-BCR can survive,
making the number of pre-B cells even more decreased with age [117]. Expression of
both the RAG and λ5 protein are controlled ultimately by the E2A gene [118-120], so the
decline of E2A expression is critical to B lymphopoiesis deficiency in aging [121].
20
Innate immunity and macrophage
Innate immunity is the first line of defense that pathogenic organisms will meet
once they enter the host body. Macrophages, polymorphonuclear leukocytes, and mast
cells are the major defense cells in innate immunity. Microbial pathogens usually
express certain conserved metabolic products, called pathogen-associated molecular
patterns (PAMPs), on their surface. PAMPs can be recognized by the pattern
recognition receptors (PRPs) generated by the innate immunity defense cells and initiate
a series of host defense reactions including proinflammatory responses, opsonization,
phagocytosis, and apoptosis [122]. The innate immunity system is made of several cell
types, and macrophages play an especially important role within those cells.
Macrophages are among the first responders to pathogenic invasion and are actively
involved in the phagocytosis of invading pathogens. In addition, macrophages can
regulate the function of neutrophils, natural killer (NK) cells, dendritic cells, and connect
the innate immunity to an adaptive immune reaction [123].
No change is witnessed in macrophage number with age in humans, but is
increased in mice with age[123]. “Inflamm-aging” is a phenomenon frequently
observed in healthy aged persons, this hyperinflammatory state is associated with higher
levels of proinflammatory cytokines, suggesting there is a chronic activation of
macrophages with age [124]. In contrast to what was observed in vivo, in vitro studies
show a diminished function of macrophages in aged animals. Macrophages from aged
mice produce less pro-inflammatory cytokines like LPS-induced TNF-α, IL-6, IL-1β, and
IL-12 [125]. This is because a subset of PRRs that mediate the activation of
macrophages, such as the Toll-like receptors (TLRs), have a lower level of expression
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[126]. Meanwhile, old macrophages have a reduced capability to migrate, adhere,
opsonize, and phagocytize the invading organism [127]. It is still not clear whether this
is caused by a deficiency in the phagocytosis- promoting receptors (the mannose
receptor, scavenger receptor, MARCO, MER, PSR, CD14, and CD36) and downstream
signaling pathways. Other important functions of macrophages, like antibacterial
peptide secretion in antibacterial defense and angogenic/fibrogenic growth factor
production in wound repair, decline with age too [123]. Also, the macrophages from
old human or rodent express less class II MHC and consequently provide suboptimal
signals to the T cell to induce adaptive immunity [128]. Thus, the overall ability of the
elderly to fight the disease-causing pathogen is reduced.
Proteasome degradation pathway in aging
In addition to declining cell function in the immune system with age, reduced
cellular degenerations within the aging body are associated with accumulation of
abnormal proteins in the cell. The synthesis/degradation balance of protein is crucial to
preserve cell function in cell cycle/differentiation regulation, transcriptional control,
DNA repair, antigen processing and apoptosis [129]. One of the main proteolytic
systems responsible for protein turnover is the proteasome. So, one of the hypotheses
raised to explain the damaged cellular protein build-up, and subsequent decline in cell
function, is the breakdown of the proteasome degradation pathway with age [130].
Components and function of ubiquitin-proteasome pathway
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For degradation, most of the known protein substrates of the proteasome will first
be covalently attached to a polyubiqutin chain. It is this polyubiquitin chain that is
recognized by and serves as a substrate signal for the proteasome. Ubiquitin (Ub) is a
conserved protein of 76 amino acids, and polyubiquitination is a multi-step process which
needs the sequential help of three enzymes: an ATP-dependent ubiquitin-activating
enzyme (E1), an ubiquitin-conjugating enzyme (E2), and an ubiquitin-protein ligase (E3).
This cascade covalently links the C-terminal glycine residue of ubiquitin to a ε-amino of
a lysine residue of the target protein. Additional ubiquitin molecules are conjugated to
lysine 48 (Lys48) of the preceding ubiquitin [131]. The specificity of the polyubiquitin
chain added to a protein is determined by the E2 and E3 enzymes, which are induced by
different types of post-translational modifications of the target protein, such as
phosphorylation [132], dephosphorylation [133], alkylation [134], or association with
ancillary proteins [135]. Thus, entry of substrate into the ubiquitin-proteasome
proteolytic pathway is regulated independently of selectivity by the proteasome.
The proteasome is a complex comprised of several subunits and exists in various
molecular forms, including 20S proteasome, 26S proteasome, and PA28-20S proteasome
complexes [129, 130]. The 20S proteasome is the catalytic core of all three
proteasomes and is present in a latent form in cells, but can be activated by heat treatment
or addition of low concentrated detergent [136, 137]. Mostly, 20S proteasome degrades
the oxidatively modified protein [138, 139]. Also, two different types of proteasome
regulatory complexes that bind to the ends of the 20S proteasome can activate it. The
addition of a 19S regulatory complex (PA700) to each end of the 20S proteasome results
in the formation of the 26S proteasome [129]. Generally, it is the 26S proteasome that
mediates the degradation of a polyubiquitinated protein and the 19S regulator functions to
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recognize the polyubiquitin signal [140, 141]. The PA28-20S complex is composed of
the 20S catalytic core and an 11S regulator (PA28) [142]. The PA28-20S complex does
not participate in the degradation of ubiquitinated substrate, but is important in antigen
presentation [142-144].
Before a protein becomes associated with the proteasome and is ultimately
degraded in it, the protein substrate needs to first disassociate from the conjugated
ubiquitin, which is catalyzed by ubiquitin-C-terminal specific processing proteases
(UBPs) or ubiquitin carboxy-terminal hydrolases (UCHs). This is an important step
because it can: 1) disassemble the polyubiquitin chain and release free ubiquitin to keep
sufficient free ubiquitin supply; 2) “proofread” mistakenly ubiquitinated proteins; 3) trim
“abnormally” long polyubiquitin chains so that they will be recognized by the 19S
regulatory complex; 4) prevent the ubiquitin-binding sites on 26S proteasome being
occupied by pure polyubiquitin chain instead of ubiquitinated substrate; and 5) activate
biosynthetic precursors by removing ubiquitin [145, 146].
Impairment of ubiquitin-proteasome pathway in aging
It is believed that the ubiquitin-proteasome degradation pathway is impaired in
aging, although the specific step being most affected is still unclear.
The efficiency and accuracy of a polyubiquitin chain being added to the substrate
protein is closely related to how quick the protein will be recognized by the 26S
proteasome and degraded. No enzymes in the ubiquitin system are proven to have a
functional change with age [145]. However, Heydari et al found that in hepatocytes
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isolated from aged rats, caloric restriction feeding can increase the heat shock induction
of ubiquitin mRNA when compared to free access diet [147]. These data indicate that
defects in the ubiquitin system associated with age are likely existing in ubiquitin
expression which is also approved in aged rat soleus muscle [148]. The impairment of
ubiquitin system function was also found in age-related diseases. For example, the
ubiquitin system works as a neuro-tissue repair mechanism in normal brain, but in
Alzheimer’s Disease (AD) patients, the generation of aberrant tau and beta amyloid
proteins is related with the accumulation of free ubiquitin and abnormally phosphorylated
tau protein as well as ubiquitin-conjugated beta amyloid protein [149].
In aging, the observation of ubiquitin-protein conjugates accumulated in different
tissues also indicates a decreased proteasome function with age. Decline in both
proteasome activity [150] and proteasome subunit expression [10] in aging has been
reported. The gene expression of proteasome subunits decreases with age in various
cell types, including human fibroblasts [10], human epidermal cells [151], and rat skeletal
myocytes [152]. The down-regulated proteasome expression is correlated with
accumulation of oxidized proteins [151, 153]. Declined proteasome function with age
has been observed in numerous tissues, but not universally in all tissues [130, 150].
Generally, this is due to a significant and consistent age-related decline in PGPH activity
in the proteasome [154]. Interestingly, as an enzyme, proteasome itself is the target of
oxidative damage and shows an age-related decline in peptidase activity [150, 155].
Also, highly oxidized protein may form intra-molecular cross-linking that resistant to
proteolysis in proteasome, this will further impair the proteasome activity with age [156-
158]. In T cells from the elderly, decreased proteasome-mediated degradation will
affect the T cell function greatly. In aged, TNF-α-treated T cells, degradation of IκBα
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is severely compromised, which causes decreased NFκB induction and interleukin-2 (IL-
2) receptor expression [159], and consequently increases TNFα induced-apoptosis [160].
Similar age-related decline in the 26S proteasome-associated enzymatic activity is also
found in both naïve CD45RA+ and memory CD45RO+ T cell subsets [161]. Another
possible explanation for the increased ubiquitin conjugates in the elderly is the
impairment of deubiquitinating enzymes. Deletion of S. cerevisiae UBP14 results in
accumulation of free ubiquitin chains and inhibition of proteolysis, presumably because
some accumulated chains are too long for ubiquitinated substrates to bind to the
proteasome [162]. In AD patients, the deubiquitinating enzymes fail to disassemble the
mutant form of ubiquitin, named Ub(+1), from the polyubiquitin chain, and this
conquently leads to the neurodegenerative disorder [163].
In conclusion, one or more steps in the ubiquitin-proteasome pathway may be
affected during the process of aging. The factors influencing the proper function of
ubiquitin-proteasome system include, but are not limit to, the modification of the
substrate protein, ubiquitin expression, proteasomal enzyme activity and de-
ubiquitination.
Ubiquitination and Signaling Regulation
In the past, most ubiquitination studies have been focused on its association with
the proteasome and the proteolytic function in protein turnover. More and more
evidence now tells us that ubiquitination also plays an important role in signaling
pathways that are proteolysis-independent [164, 165].
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Proteins can be either polyubiquitinated or monoubiquitinated. The well-known
polyubiquitination (polyUb) that can lead to the degradation of substrate protein in the
26S proteasome occurs through residue Lys48. Another type of polyUb, in which
ubiquitins are linked through Lys63, can control the protein activity without the
proteasomal degradation. Besides TNF-α, engagement of IL-1β can trigger NF-κB’s
activity too. Activation of NF-κB requires the separation of NF-κB from its inhibitor
IκB by ubiquitinating and sending IκB to 26S proteasome for degradation [166].
Ubiquitination and degradation of IkB is triggered by activated IKK, whose function is to
selectively phosphorylate IkB at serine residue 32 and 36 [167]. In IL-1β induced NF-
κB pathway, function of IKK is regulated through TRAF6 and TAB [168]. TRAF6
contains RING domain E3 Ub ligase activity and can self-ubiquitinate to form Lys63-
linked polyUb chain upon IL-1β stimulation. This then results in the sequential
activation of TAB and IKK and leads to NF-κB activation [169]. Addition of
proteasome inhibitor MG132 or lactacystin can not inhibit the activity of IKK induced by
TRAF6 [169], therefore, in this case, ubiquitination is acting independent of the
proteasome. Proteasome-independent ubiquitination also exists in other steps of NF-κB
signaling. PolyUb through Lys63 also form on IKKγ, the regulatory subunit of IKK
complex and enhance the overall activity of IKK [170-172]. Studies by Spence et al
also showed that a ribosomal protein, L28, is modified by a Lys63-linked polyUb chain
when ribosomes are actively involved in translation. The level of L28 ubiquitination
varies with cell cycle stage, where it is high in S phase but low in G0 and G1 phase.
Since L28 itself is quite stable, no proteolytic action is involved in this case [173].
Monoubiquitination can also regulate the protein function in a reversible, non-
proteolytic manner. Sometime, monoubiquitin serves as a sorting signal that determines
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newly synthesized protein being delivered to plasma membrane or internalized receptor
protein being delivered to lysosome [174]. Interestingly, some proteins can be either
monoubiquitinated or polyubiquitinated and lead to different protein function. PCNA
(proliferating cell nuclear antigen) is a protein involved in DNA replication and repair
[175]. Under normal situation, PCNA is sumoylated. While after exposure to UV or
chemicals, PCNA is monoubiquitinated at the same site, which will result in DNA
damage-induced mutagenesis [176]. Contrast to the monoubiquitination, Lys63-linked
polyubiquitination on PCNA will lead to an error-free DNA repair [175].
Ubiquitination has a lot of features similar to another protein modification
system--phosphorylation. First, ubiquitination can be induced by upstream signaling
events. Stimulation of epidermal growth factor-receptor (EGFR) can induce the
monoubiquitination of Eps15 by Nedd4, Eps15 will then participate in subsequent signal
transduction [177]. Second, ubiquitination, especially monoubiquitination can be
recognized by proteins containing Ub-binding domains. To date, four types of Ub-
binding domains have been found, including the ubiquitin associated (UBA) domain,
ubiquitin interacting motif (UIM), ubiquitin E2 variant (UEV) and Cue1-homologous
(CUE) [164]. These domains have their own specificity and affinity for ubiquitin
modified at different sites. Third, the ubiquitination can be regulated and removed by
de-ubiquitinating enzymes. The polyUb chain attached to TRAF6 or IKKγ can be
removed by the cyclindromatosis tumor suppressor protein (CYLD) and NF-κB activity
is down-regulated [178-180]. Thus, the type of ubiquitination modification, its receptor,
and the de-ubiquitinating enzyme form an interactive network that may work as another
important regulatory system like phosphorylation.
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Aging, T cell function and Cbl-b 
 
The Cbl family was first identified as an oncogenic mouse retrovirus, named v-
Cbl, for Casitas B-lineage Lymphoma [181]. Since then, three mammalian homologues
(Cbl, Cbl-b and Cbl-3) have been characterized [182-184]. These proteins have highly
conserved amino-terminal regions which contain: 1) a tyrosine-kinase-binding (TKB)
domain that recognizes phosphorylated tyrosine on activated protein tyrosine kinase
(PTK); 2) a RING finger domain that functions as E3 ubiquitin ligase, and induces
ubiquitin conjugation to activated PTK [185-187]. Besides these common N-terminal
structures within the whole Cbl family, Cbl and Cbl-b share some additional features in
their carboxyl-terminal regions. They both contain proline-rich regions that lie in the
carboxyl-terminal half of the protein, and are believed to be involved in SH3-domain
interaction [185]. Also, they have tyrosines at 709 and 655, which can bind to various
signaling intermediates that containing SH2 domains, and are substrates of tyrosine
kinases [188]. The phosphorylated Cbl-b is activated and then mediates
polyubiquitination and down-regulation of these proteins. Therefore, as E3 ubiquitin
ligase, a major function of Cbl family proteins is ubiquitinating activated PTKs and
mediating their down-regulation. On the other hand, as an adaptor protein, Cbl is
associated with various proteins that are essential to signal transduction, and change their
intercellular location and interaction with other proteins, thus providing another way to
regulate signaling pathway in addition to its E3 ubiquitin ligase activity. Cbl and Cbl-b
are found in a variety of normal tissues and hematopoietic cell lines. cbl mRNA is most
abundant in testis and thymus while the highest cbl-b mRNA levels are observed in
spleen [182, 189]. The expression of cbl and cbl-b mRNA can be modulated during the
differentiation of several hematopoietic cell lines [182, 190]. Induction of proliferation
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will not change the expression level of cbl [190] but will down-regulate Cbl-b expression
in BALB/c splenic T-lymphocytes [191]. These data suggest that Cbl and Cbl-b may
have differential effects on regulation immune system. Both Cbl and Cbl-b are crucial
in T cell signaling regulation. Because they have a highly homologous structure, Cbl
and Cbl-b have some important overlapping functions, such as promoting TCR down-
regulation after ligand engagement [192], suppressing the activation of downstream
proteins upon TCR stimulation [193, 194], and inhibiting growth factor induced
proliferation [195-197]. More importantly, Cbl and Cbl-b show selectively regulation
on T cell system at different aspect. Cbl-deficient mice show hypercellularity of
lymphoid organs and altered positive selection in the thymus [198]. Thymocytes from
these mice show a marked activation of Zap-70 in response to TCR stimulation and
increased intracellular protein phosphorylation and surface receptor expression in
CD4+CD8+ DP thymocytes [199]. The Cbl-b-deficient mouse shows a similar
phenomenon, but in peripheral T cells with hyperactivation of Vav as opposed to
thymocytes having increased Zap-70 activation. T cells in these mice show enhanced
proliferation and IL-2 production in response to TCR triggering, and uncouple T cell
proliferation from the costimulaiton of CD28 signal [200, 201], which indicates a
lowered threshold for TCR signaling in Cbl-b-deficient mice. As a result, these mice
have an increased susceptibility to the development of autoimmunity. So, in T cell
regulation, Cbl controls thymocyte selection and development, while Cbl-b plays its role
in peripheral T cell activation [185, 186, 202].
Many signaling pathways in different tissues and cell lines are influenced by Cbl-
b, including calcium signaling [203], Lyn-Syk-LAT or Gab2-mediated complementary
signaling pathway [204], activation of p21-activated kinase (PAK) [205], insulin-
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stimulated glucose transport [206], EGFR induced apoptosis [207], chemotaxis [208],
cancer transforming [209], and Ig class switch or germinal center formation [210]. The
extent of Cbl-b's participation in signaling pathways in peripheral T cell activation is not
well understood. It has been shown that upon TCR stimulation, Cbl-b is phosphorylated
by protein tyrosine kinase of the Syk-(Syk/Zap-70) or Src-(Fyn/Lck) family [188].
Phosphorylated Cbl-b has higher affinity for CIN85 (Cbl-interacting protein of 85 kDa)
to catalyze the ubiquitination and degradation of receptor tyrosine kinase [211]. In
downstream events, Cbl-b can interact with, and direct ubiquitination to, the p85
regulatory subunit of phosphatidylinositol-3-kinase (PI(3)K), which phosphorylates
phosphatidyl inositol (PI) to form bioactive lipid product, PI(3,4,5)P, that act as second
messengers in signaling transduction [212]. The ubiquitination of PI(3)K does not lead
to the proteolysis of PI(3)K, but blocks the association of p85 to CD28 and TCRζ [213].
Since the product of PI(3)K can bind and regulate Vav, by inducing ubiquitination of
PI(3)K, Cbl-b indirectly regulates the exchange activity of Vav and the organization of
receptor clustering and raft aggregation, which is essential for a successful TCR-induced
T cell activation [214, 215]. Besides p85, Cbl-b can also bind to Zap-70, Lck, PLCγ-1.
Expression of these Cbl-b binding proteins remains unchanged [200] in cbl-b-deficient T
cells suggesting that Cbl-b can regulate the function of these proteins in a proteolytic-
independent manner similar to Vav regulation. In agreement of these observations that
role of Cbl-b in T cell signaling is quite crutial, loss of Cbl-b has profound impact on T
cell function. cbl-/-CD4+CD25- T effector cells show defects in TGF-β signaling
pathway [216, 217]. Th1 cells without Cbl-b expression is tolerant to apoptosis induced
by CD3 ligation [218]. Cbl-b deficiency T cells resist T cell anergy induction by
ionomycin [219].
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Considering that Cbl-b functions as a key regulator in T cell activation, the
mechanism by which Cbl-b itself is regulated within the signaling network attracts more
and more attention of current research. Previous work suggests Cbl-b is regulated by
CD28-mediated co-stimulation since CD28-/- cbl-b-/- mice have increased proliferation
compared to CD28-/- cbl-b+/+ mice [200, 201]. A recent study in Zhang’s lab has also
shown that CD28 co-stimulation selectively induces greater ubiquitination and
degradation of Cbl-b in wild-type BALB/c T cells than CD3 stimulation alone, and TCR-
induced Cbl-b ubiquitination and degradation are significantly reduced in CD28-deficient
T cells [191]. It is already known that Cbl-b can be ubiquitinated by either HECT
(homologous to the E6-AP carboxyl terminus) E3 enzyme [220] or by itself though its
RING finger E3 activity [221]. The subsequent degradation of ubiquitinated Cbl-b
depends on proteasome only [220] or both the proteasome and lysosome [221].
However, the expression of Cbl-b in old T cells, its regulation upon stimulation, and its
relationship with immunosenescence are still unclear. Answering these questions will
be the main target of this proposal.
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Chapter 2: CD28 Activation Down-regulate Cbl-b Expression in Young
Rat Splenic T-lymphocyte
2.1 ABSTRACT
It is well known that T-lymphocyte proliferation declines in vitro with age, and is
associated with decreased expression and/or activity of stimulatory intracellular signaling
proteins. However, the role of inhibitory intracellular signaling molecules like the
ubiquitin ligase Cbl-b in regulating T-lymphocyte function in aging is largely unknown.
Therefore, we tested the hypothesis that T-lymphocyte proliferation might influence the
expression of Cbl-b or vice versa. We show that young splenic T-lymphocyte reduced
Cbl-b expression when stimulated with anti-CD3 and anti-CD28 antibodies, while anti-
CD3 antibody alone unable to down-regulate Cbl-b expression. This effect appeared to
be due to post-translational binding and modification by another ubiquitin ligase Nedd4.
The mechanism for Cbl-b down-regulation may involve the proteasome since blocking
proteasomal activity in young T-lymphocytes prevented Cbl-b down regulation. These
data provide evidence for a novel relationship of T-lymphocyte function with
ubiquitin/proteasome pathway and support the idea of further study in role of Cbl-b in
aging-associated reduced T-lymphocyte response.
2.2 INTRODUCTION
As a negative regulator of T cell signaling pathway, Cbl-b’s function have been
frequently studied to see how they are involved in down-regulating other proteins’,
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mostly, tyrosine kinases’, expression and activity. However, who would control the
expression of Cbl-b, what is the entire mechanism, how the regulation on Cbl-b will
affect the function of Cbl-b’s target in T cell signaling transduction are barely known.
Research from different labs gave different stories about regulation of Cbl-b.
Regulation of Cbl-b was first studied in EGF stimulated MDA-MB-468 breast
cancer cell line. Stimulation of EGF induces the degradation of both EGFR and Cbl-b.
This coordinated degradation requires the association of EGFR with Cbl-b and there is a
stoichiometric relationship between these two proteins. Experiment using different
inhibitors shows that both proteasome and lysosome are involved in their degradation.
The regulation mechanism can not tell the difference between Cbl-b and Cbl, since co-
expression of Cbl and EGFR show the same co-degradation result. Detailed study
shows that Cbl-b is ubiquitinated and self-degraded. Experiments with mutants of Cbl-b
find that TKB and RING finger domain of Cbl-b are indispensable for the proper down-
regulation of itself. More specifically, point mutation in Cbl-b’s RING finger (C373A)
will completely eliminate the EGR-induced down-regulation of the EGRF and Cbl-b
[221].
In splenic T cells isolated from WT BALB/c mice, Cbl-b is ubiquitinated and
degraded when cells are activated by either plate-bound anti-CD3 or anti-CD3 plus anti-
CD28 antibodies. The extent of ubiquitination and degradation are greater when CD28
costimulatory signal is present. The level of Cbl-b ubiquitination also correlates with
the level of T cell response. Thus, Cbl-b ubiquitination and degradation induced by
CD28 costimulation partly set the threshold of T cell activation [191].
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Two domains of Cbl-b, proline-rich region and the phosphotyrosine binding
domain, can bind with the WW domains on Nedd4 both in vivo and in vitro [220].
Nedd4 is an E3 ubiquitin ligase using HECT (homologous to the E6-AP carboxyl
terminus) domain as its catalytic motif. Structure of Nedd4 family protein all contain a
C2 domain and 2-4 WW domains at N-terminal, and the catalytic HECT domain at C-
terminal [222]. C2 domain’s function is to localize the Nedd4 to membrane by
association with the phospholipid at membrane surface [223]. WW domain is the
substrate recognition part of Nedd4 [224]. HECT domain catalyzes the addition of
ubiquitin to its substrate, and results in the ubiquitinated target be sent either to 26S
proteasome for degradation or to lysosome for recycling or endocytosis [225]. Thus,
Nedd4 family proteins are involved in a number of diverse cellular processes, especially
the signaling of membrane associated protein.
In transfected 293T human embryonic kidney cells, the association between Cbl-b
and Nedd4 has functional importance, since Nedd4 can ubiquitinate Cbl-b and lower Cbl-
b protein level by proteasomal degradation and subsequently reverse the Cbl-b-mediated
ubiquitination and degradation of EGFR and Src. Other WW domain-containing HECT
E3s, like Itch, have the same effect on Cbl-b [220]. However, whether these findings
observed in transfected system have an in vivo significance in human and mouse primary
cell and how the regulation events be connected to cell receptor activation are still
unknown.
Opposing to the replicative immune response, when accompanied with different
transcriptional partner, sustained Ca2+ and calcineurin could induce T cell anergy or
tolerance [226], characterized by a low IL-2 secretion and low proliferation,
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hyporesponsive state upon restimulation [227]. Long term exposure of mouse D5 (Ar-
5) TH1 cell to ionomycin will induce the anergy state of cells, and increase the mRNA
level of Cbl-b and Itch but not Nedd4 [203]. This experiment shows that the altered
transcription profile cause by T cell anergy are responsible for the regulation of Cbl-b
mRNA expression. The detailed mechanism underlying the Cbl-b regulation and
whether this regulative process is special for T cell anergy or can be applied to general
situation like normal TCR-mediated cell activation are not clear now.
Another research in T cell anergy found that expression of Egr-2 and Egr-3 are
increased in anergy. Egr-2 and Egr-3 are two members of zinc-finger transcription
factor Egr (early growth response) family. They can regulate the target gene
transcription by binding to its canonical binding site (5’-GCGGGGGCG-3’) on target
gene promoter [228]. The upregulation of Egr-2 and Egr-3 in anergy has correlation
with Cbl-b since the co-upregulation of Cbl-b’s expression disappear in Egr-3-/- T cells
[229]. Whether Egr-2 and/or Egr-3 bind directly to Cbl-b’s promoter or indirectly
upregulate Cbl-b is unclear now.
The goal in this chapter is to see under normal stimulation condition, whether
Cbl-b’s expression will change in primary rat T cells and try to figure out the possible
pathway that Cbl-b being regulated.
2.3 MATERIALS AND METHODS
Materials
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Anti-Cbl-b antibody (G-1), anti-Cbl antibody (C-15), and anti-β-actin (I-19) were
purchased from Santa Cruz (Santa Cruz, CA). Anti-CD3 (G4.18) and anti-CD28
(JJ319) monoclonal antibodies were purchased from BD PharMingen (San Jose, CA).
The proteasome inhibitor MG-132 and lactacystin were purchased from Calbiochem (La
Jolla, CA). All cell culture media were purchased from Mediatech (Herndon, VA) and
all other chemicals were reagent grade or higher and from Sigma-Aldrich (St. Louis,
MO).
Animals
Male, 4-6-month (young) Sprague-Dawley rats were purchased from Harlan
Sprague Dawley (Indianapolis, IN) and maintained on a standard chow diet. All animal
procedures were approved by the University of Texas Animal Use and Care Committee.
T-lymphocyte isolation and culture
Rats were sacrificed and spleens aseptically removed. Single splenic cell
suspensions were isolated by homogenization and filtering through a 25mm syringe filter.
Lymphocytes were isolated via differential migration following centrifugation in
Lymphocyte Separation Medium (Mediatech, Herndon, VA). T-lymphocytes were
isolated using negative selection Immulan columns (Biotecx, Houston, TX) per
manufacturer’s instructions as previously described [230]. T-lymphocytes were counted
using the Cell-Dyn 900 Hematology Analyzer (Sequoia-Turner, Mountainview, CA).
T-lymphocytes, 2.5x107 cells per petri dish, were stimulated at 37ºC for designated time
in pre-warmed complete culture media (RPMI 1640 supplemented with 10% heat
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inactivated fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 mM 2-
mercaptoethanol, 2 mM L-glutamine and 25 mM HEPES buffer) with 10 µg/ml anti-CD3
plus 1 µg/ml anti-CD28 antibodies, 10 µg/ml plate-bound anti-CD3, 1 µg/ml anti-CD28
antibody only, or 5 µg/ml anti-CTLA-4 antibody. In the proteasome inhibition
experiments, the MG-132 was dissolved in DMSO (25mM stock solution) and used at a
1:500 dilution (50 µM) in the cell culture media or lactacystin (5 mM stock solution) was
used at a 1:1000 dilution (5 µM) and added simultaneously with the antibodies. To
inhibit the lysosome activity, NH4Cl (5 M stock solution) was used at a 1:500 dilution (10
mM) in the cell culture media.
Western immunoblotting
Cellular protein was isolated and western immunoblotting performed as
previously described [231]. Briefly, total protein from stimulated or unstimulated T-
lymphocytes were pelleted and lysed in 50 µl of lysis buffer containing 50 mM Tris (pH
7.4), 10 mM EDTA, 150 mM NaCl, 0.1% Tween 20, 1 µl/ml β-ME, and 7 µl/ml protease
inhibitor mix. Lyastes were centrifuged and the protein containing supernatant was
quantitated using the Bio-Rad protein assay (Bio-Rad, Hercules, CA). 30 µg of total
protein was separated by SDS-PAGE along with Bio-Rad’s Kaleidoscope Prestained
Standards. The protein was transferred onto PolyScreen PVDF membranes (NEN Life
Sciences, Boston, MA) and the membranes blocked with 15 ml blocking solution
containing 25 mM Tris (pH 8.0), 125 mM NaCl, 4% non-fat milk, and 0.1% Tween 20
prior to probing with anti-Cbl-b antibody (1:3000 dilution in 15 ml blocking solution) or
anti-Cbl antibody. Immunoreactive bands were detected using an alkaline phosphatase-
conjugated goat-anti-rabbit secondary antibody and CDP-Star chemiluminescence
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reagent (NEN Life Sciences, Boston, MA). Densitometry was performed using a BioRad
Gel Documentation System. The membrane was also probed with an anti-β-actin
antibody to control for lane loading variation.
RNA Isolation and RT-PCR
T-lymphocyte RNA was isolated from whole cells by acid guanidinium
thiocyanate-phenol-choloroform extraction method. Briefly, 10x106 cells were pipetted
repeatedly in 1 ml RNA STAT-60TM (TEL-TEST “B”, INC, Friendswood, TX). Cell
suspensions were stored for 5 min at room temperature then 200 µl of chloroform was
added for each ml of RNA STAT-60TM used. Samples were vortexed vigorously for 15
sec and allowed to stand at room temperature for 2-3 min. Following centrifugation at
12,000 g for 15 min at 4ºC, the homogenates were separated into a lower
phenol/chloroform phase and the RNA in the upper aqueous phase was transferred to
fresh tubes containing 500 µl isopropanol. After standing at room temperature for 5
min, samples were centrifuged at 12,000 g for 10 min at 4ºC. The supernatant was
removed and the RNA pellet was washed once with 1 ml of 75% ethanol by vortexing
and subsequent centrifugation at 7,500 g for 5 min at 4ºC. The RNA pellet was dried
briefly by air-drying and dissolved in diethylpyrocarbonate (DEPC)-treated water by
vigorous pipetting and gentle heating at 55ºC for 10 min. RNA was quantitated
spectrophotometrically by UV-1201S UV-VIS spectrophotometer (Shimadzu, Columbia,
MD).
For cDNA synthesis, 2 µg of RNA was combined with 1 µg of random primer, 5
µl of 10 µM dNTP mix, 40 u of RNasin plus RNase inhibitor, 5 µl of M-MLV RT 5X
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buffer, and 200 u of M-MLV reverse transcriptase (Promega, Madison WI) in a 25 µl
total reaction volume using the PerkinElmer GeneAmp PCR system 2400 (PerkinElmer,
Wellesley, MA) to reverse transcribe (RT) and amplify template RNA. The RT reaction
used was 4ºC x 10 min, 15ºC x 10 min, 22ºC x 10 min, 37ºC x 60 min, and 95ºC x 5min.
mRNA levels of Cbl-b, Nedd4, and GAPDH were analyzed by PCR reaction. 2
µl of RT solution was combined with 20 pM of each primer and 12.5 µl of PCR Master
Mix (Promega, Madison WI) in a 25 µl total reaction volume and PCR reaction was
performed with 25 cycles of denaturation: 1 min at 94°C; annealing: 1 min at 52°C; and
extension: 2 min at 72°C using the PerkinElmer GeneAmp PCR system 2400. Primer
sequences are listed in Table 2.1. The PCR products were then separated on a 1%
agarose gel, stained with ethidium bromide, and scanned by a CCD camera. The band
intensities were then analyzed by BioRad Gel Documentation System.
Table2.1 PCR primer sequences for RT-PCR
Gene amplified Primer sequence 
Cbl-b Forward primer 5’-GGTCACTGTATACTGAATGG-3’ 
 Reverse primer 5’-ATTGAGACGTGGCGAGACGG-3’ 
Nedd4 [232] Forward primer 5’-CCAGATGCTGCTTGCCATTTGCAG-3’ 
 Reverse primer 5’-GTAATCCCTGGAGTAGGGCACTGC-3’ 
GAPDH Forward primer 5’-CCATGGAGAAGGCTGGGG-3’ 




Stimulated or unstimulated T-lymphocytes from 4 rats were pooled together.
Pooled T-lymphocytes were pelleted and total protein lysed in 500 µl of lysis buffer
containing 50 mM Tris (pH 7.4), 10 mM EDTA, 150 mM NaCl, 0.1% Tween 20, 1 µl/ml
β-ME, and 7 µl/ml protease inhibitor mix. Lyastes were centrifuged and the protein
containing supernatant were pre-cleared by adding 40 µl of protein A/G plus agarose
(Upstate, Charlottesville, VA) and rotated at 4ºC for 1 hr. The mixture was pelleted at
2,000 g for 2 min at 4ºC and supernatant was quantitated using the Bio-Rad protein assay
(Bio-Rad, Hercules, CA). 500 µg of total protein were incubated with 4 µg anti-Cbl-b
antibody (H-454) and rotated overnight at 4ºC. Protein A/G plus agarose (20 µl) was
added and the mixture was rotated again at 4ºC for 2 hr. The mixture was pelleted at
2,000 g for 2 min at 4ºC and the beads washed 3 times with 500 µl lysis buffer. The
bead slurry was suspended in 2X Laemmli sample buffer, boiled for 10 min and the
supernatant (immunoprecipitated protein) was collected.
Phosphoprotein staining
Immunoprecipitation of Cbl-b are performed as described before. Half of the
sample were separated using standard SDS-PAGE techniques. Gels were fixed in 50%
methanol : 10% acetic acid solution two times for 30 min each at room temperature and
washed three times in ultrapure water for 10 min each. Gels were stained for
phosphorylated proteins using Pro-Q Diamond Phosphoprotein Gel Stain (Invitrogen,
Carlsbad, CA) for 90 min at room temperature. Gels were destained to reduce the
background signal using 5:75:20 1M sodium acetate (pH 4.0) : water : acetonitrile
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solution three times for 30 min each at room temperature. Gels were washed three times
in ultrapure water for 10 min each and phosphorylated bands were visualized using a
Molecular Dynamics FSI fluorimager (Bio-Rad, Hercules, CA) with excitation at 532 nm
and emission at 555 nm, respectively. Proteins from stained gels are not transferred
sufficiently to PVDF membranes for probing with anti-Cbl-b antibody, therefore, samples
were run in parallel, transferred and immunoblotted for anti-Cbl-b as described above.
Small scale sucrose density gradient centrifugation for protein isolation
Prepare the sucrose gradient solution by adding 950 µl of 40% Sucrose, 950 µl of
31.25% Sucrose, 950 µl of 22.5% Sucrose, 950 µl of 13.75% Sucrose, and 950 µl of 5%
Sucrose sequentially in Beckman SW55 Ti rotor tubes. Tubes of sucrose solution layers
are kept at 4°C for at least 12 to 16 hr (i.e., overnight) and a linear gradient will form.
100 µl crude cellular extract isolated with RIPA buffer (0.01 M sodium phosphate, pH
7.2, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 0.1% SDS, 1% sodium
deoxycholate, 5 µg/ml aprotinin, 50 mM sodium fluoride, 1 µg/ml leupeptin, and 20 mM
sodium vanadate) will be layered on top of the sucrose gradient solution and centrifuge at
4°C for 4 hr at 50,000 rpm (approximately 237,000 X g) in Optima XL-100K
Ultracentrifuge (Beckman, Fullerton, CA). After centrifugation, carefully transfer 300
µl of fractions from the top of the gradient to the microcentrifuge tubes with large-bore
pipette tips. Fractions will be concentrated by Ultrafree-MC 5,000 NMWL centrifugal
filter units (Millipore, Billerica, MA) and assayed by western immunoblotting.
Cell fractionation
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2 X 107 splenic T-lymphocytes with different treatment were lysed in hypotonic
buffer E containing 10 mM Tris (pH 7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT, and
7 µl/ml protease inhibitor mix for 15 min on ice. Lyastes were centrifuged and
supernatant (cytosol fraction) was collected. Pellet yielded was resuspended in
hypotonic buffer E containing 1% Nonidet P-40 and was recentrifuged to collect the
supernatant (detergent-soluble fraction). The pellet (detergent-insoluble fraction) was
resuspended in RIPA buffer (0.01 M sodium phosphate, pH 7.2, 150 mM NaCl, 2 mM
EDTA, 1% Nonidet P-40, 0.1% SDS, 1% sodium deoxycholate, 5 µg/ml aprotinin, 50
mM sodium fluoride, 1 µg/ml leupeptin, and 20 mM sodium vanadate) by sonication and
cleared by centrifugation. Protein concentration from each centrifugation step
(cytoplasm, detergent-soluble, and detergent-insoluble fractions) was determined by the
Bio-Rad DC protein assay (Bio-Rad, Hercules, CA) and was analyzed for Cbl-b and
Nedd4 expression by western immunoblotting.
20S proteasome activity assay
Proteasome activity is determined by CHEMICON 20S Proteasome Activity
Assay Kit (Chemicon, Temecula, CA) via manufacturer’s instruction. Briefly, total T
cell protein is isolated as described before and protein concentration determined. 1 mg
of total protein and 5 nM proteasome substrate (Suc-LLVY-AMC) are incubated in 25
mM HEPES (pH 7.5), 0.5 mM EDTA, 0.05% NP-40, and 0.001%SDS in 96-well
fluorometer plate (100 µl total volume) for 1 hr at 37ºC. In parallel, AMC standard
curve from 0.04 mM to 12.5 mM and proteasome positive control curve (1:4 to 1:256)
are prepared. Fluorescences are recorded in DTX 880 Multimode Detector (Beckman,
Fullerton, CA) with 380/460 nm filter.
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Statistical analysis
Data were analyzed by one-way analysis of variance (ANOVA) and statistical
difference were determined using Tukey’s multiple comparison test with GraphPad Prism
software (San Diego, CA). A p<0.05 was considered significantly different.
2.4 RESULTS
Cbl-b expression in activated splenic T-lymphocytes
T-lymphocytes were purified from rat spleens by negative selection. The T-
lymphocytes were stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml)
antibodies for 30, 60, or 120 min. The results are shown in Figure 2.1. There is a
significant 41% reduction in Cbl-b protein expression at 30 min. Similar decrease was
also observed in 60 min antibody treatment and the reduction was maximal at 120 min
post stimulation (57% reduction). As Cbl has a very similar structure with Cbl-b and
these two proteins have some overlapping functions in immune regulation, the expression
level of Cbl protein was also tested at the same time. Cbl protein expression showed a
moderate but not significant decrease upon stimulation (16%, 15% and 31% reduction at
30, 60, and 120 min). The two T-lymphocyte activating signals, CD3 and CD28 are
both presented to cause the down regulation of Cbl-b. In order to tell whether both
signals are required to control the expression of Cbl-b, purified T-lymphocytes were also
stimulated with plate-bound anti-CD3 antibody or soluble anti-CD28. Plate-bound anti-
CD3 antibody provides a stimulating signal strong enough to cause a similar proliferation
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response in T-lymphocyte as those being stimulated by soluble anti-CD3 and anti-CD28
antibodies (data not shown). Results of stimulating young splenic T-lymphocytes with
plate-bound anti-CD3 antibody are shown in Figure 2.2. Stimulation via CD3 only did
not alter Cbl-b expression in young splenic T-lymphocytes. Stimulating young splenic
T-lymphocytes with soluble anti-CD28 antibody alone decreased Cbl-b expression
significantly (67%, 59%, and 80% reduction at 30, 60, and 120 min) (Figure 2.3). No
effects were seen in Cbl protein expression.
Cbl-b expression in inhibited splenic T-lymphocytes
By competing with CD28 for costimulatory molecules expressed on APCs,
CTLA-4 can oppose CD28’s function and inhibit T-lymphocytes activation. Since
soluble anti-CD28 antibody alone can down-regulate the Cbl-b expression, whether the
inhibitory signal from CTLA-4 can control Cbl-b expression was tested. Purified young
splenic T-lymphocytes were incubated with 5 µg/ml anti-CTLA-4 antibody for 30, 60, or
120 min. The results are shown in Figure 2.4. Cbl-b expression increases after 30 min
exposure to anti-CTLA-4 antibody (133.4% compare to untreated control) and further
increased expression of Cbl-b is observed at 60 min and 120 min treatment (126.0% and
183.4% respectively).
Cbl-b gene expression in splenic T-lymphocytes under different treatment
In order to determine if the observed Cbl-b protein expression change under
different stimulatory conditions is due to the regulation on transcriptional levle or on
translational level, mRNA expression of Cbl-b gene was checked. The T-lymphocytes
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were unstimulated or stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1
µg/ml) antibodies, plate-bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1
µg/ml) antibody for 120 min and RT-PCR was performed. The results are shown in
Figure 2.5. Stimulation young splenic T-lymphocytes with different stimulatory signals
had no effect on Cbl-b mRNA expression.
Role of proteasome system in the regulation of Cbl-b expression
Cbl-b in wild-type BALB/c T cell can be ubiquitinated and degradated upon
CD28 co-stimulation, which suggests the involvement of proteasome system in the
regualtion of Cbl-b expression [191]. Proteasome inhibitors were added along with
anti-CD3 and anti-CD28 antibodies and Cbl-b expression level tested. Figure 2.6 shows
that, when the proteasomal inhibitor MG132 is added simultaneously with anti-CD3 and
anti-CD28 antibodies, activation fails to reduce Cbl-b expression at 30, 60 and 120 min in
young T-lymphocytes. Since MG132 also inhibits calpain [233], these results were
confirmed by using a more specific proteasome inhibitor lactacystin (Figure 2.7).
Indeed, stimulation did not reduce Cbl-b protein expression in the presence of
Lactacystin at 30, 60 or 120 min poststimulation in young splenic T-lymphocytes.
Degradation of Cbl-b can be lysosome-dependent too, since its degradation upon
activation of EGFR is sensitive to both proteasome and lysosome inhibitors [221]. To
test if Cbl-b was sent to lysosome for degradation too, purified T-lymphocytes were
stimulated with anti-CD3 and anti-CD28 antibodies in the presence or absence of NH4Cl,
inhibitor of lysosome and Cbl-b expression tested. As shown in Figure 2.8, NH4Cl can
not inhibit the degradation of Cbl-b stimulated by CD3 and CD28 antibodies.
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Proteasome activity in splenic T-lymphocytes with different treatment
Since the proteasome system is required for Cbl-b regulation as shown in previous
results, we need to determine the proteasome activity in splenic T-lymphocytes under
different treatment. The T-lymphocytes were unstimulated or stimulated by soluble
anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) antibodies, plate-bound anti-CD3 (10
µg/ml) antibody, or soluble anti-CD28 (1 µg/ml) antibody for 120 min and proteasome
activities in each group were determined. The results are shown in Figure 2.9. There
is no significant change in proteasome activity between each group.
Phosphorylation of Cbl-b under different stimulation condition
TCR stimulation in Jurkat T cells can induce a rapid (<10 min) tyrosine
phosphorylation on Cbl-b protein [188]. Also, in previous results, we made the
observation that mRNA level of Cbl-b didn’t change upon stimulation. All these results
suggest that post-transcriptional modification, especially tyrosine phosphorylation may
play an important role in regulating Cbl-b’s function and other activities. Thus, the
tyrosine phosphorylation of Cbl-b upon stimulation was determined. The results are
shown in Figure 2.10. In both plate-bound anti-CD3 stimulated and soluble anti-CD28
stimulated T-lymphocytes, Cbl-b started being phosphorylated 5 min after stimulation.
The phosphorylation level increased at 30 min and continued till 120 min. No
significant difference of Cbl-b tyrosine phosphorylation was seen between plate-bound
anti-CD3 stimulated and soluble anti-CD28 stimulated condition.
Association of Nedd4/Itch protein with Cbl-b protein
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HECT E3 ubiquitin ligases Nedd4 and Itch mediate the proteasomal degradation
of Cbl-b protein in transfected 293T cells [220], which implies that Nedd4 and Itch may
also play an important role in the regulation of Cbl-b protein in rat splenic T-
lymphocytes. The T-lymphocytes were unstimulated or stimulated by soluble anti-CD3
(10 µg/ml) plus anti-CD28 (1 µg/ml) antibodies, plate-bound anti-CD3 (10 µg/ml)
antibody, or soluble anti-CD28 (1 µg/ml) antibody for 120 min. The association of
Nedd4 or Itch with Cbl-b was then determined by immunoprecipitation in splenic T-
lymphocytes. The results are shown in Figure 2.11. There was a constant association
between Nedd4 and Cbl-b even when T-lymphocytes were not stimulated, but the extent
of association were increased when T-lymphocytes were stimulated. Also, no
association between Itch and Cbl-b was observed under either stimulatory condition or
rest condition.
Subcellular localization of Nedd4 with different treatment
In Nedd4-mediated PLC-γ1 degradation, the subcellular localization of Nedd4
was changed [203] to be close to its substrate, suggesting that Nedd4 may use the same
mechanism to regulate Cbl-b expression. The subcellular localization of Nedd4 and
Cbl-b were tested via small scale sucrose density gradient centrifugation, which is
frequently used for separating cell organelles from crude cellular extracts and
determining the protein location within the cell. The results are shown in Figure 2.12.
It showed that Cbl-b expressing location did not change with different stimulatory
signals, most of the Cbl-b proteins were expressed at lane 2 and 3. Subcellular location
of Nedd4 was more dispersed at resting condition that Nedd4 protein was distributed
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from lane 2 to lane 6 (Figure 2.12a). After different stimulatory treatment, Nedd4
showed different subcellular movement pattern. When anti-CD28 antibody was present,
Nedd4 expression showed translocation to lane 2 and 3, which was where Cbl-b protein
was located in the T-lymphocytes. Compared to unstimulated T-lymphocytes, 18%
more Nedd4 was translocated to lane 2 and 3 if anti-CD3 plus anti-CD28 antibodies were
added (Figure 2.12b), and 40% more if only anti-CD28 antibody was added (Figure
2.12d). When T-lymphocytes were stimulated with anti-CD3 antibody only, similar
translocation was not observed in Nedd4 protein (Figure 2.12c).
Relative cytoplasm expression of Nedd4 and Cbl-b
Since proteins contained in lane 3 in previous result include both cytoplasm and
lipid raft portion (data not shown), the cytoplasm and lipid raft portion of T-lymphocytes
were isolated respectively and Cbl-b expression determined. The result showed that in
splenic T-lymphocytes Cbl-b can only be found in cytoplasm portion. Thus, the relative
expression of Nedd4 vs. Cbl-b in cytoplasm portion was determined. The results are
shown in Figure 2.13. Cbl-b showed highest expression when T-lymphocytes were
stimulated by plate-bound anti-CD3 only, while under the same stimulation condition,
Nedd4 expression was lowest. Cytoplasm expressions of Cbl-b and Nedd4 in T-
lymphocytes with different treatment were reversely related.
Nedd4 expression in activated splenic T-lymphocytes
In order to know the change of Nedd4 expression in T-lymphocyte cytoplasm is
caused solely by intracellular transportation or the protein or gene expression of Nedd4
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change with stimulation too, the Nedd4 protein expression was first determined in T-
lymphocytes that were stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1
µg/ml) antibodies, plate-bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1
µg/ml) antibody for 120 min respectively. As shown in Figure 2.14, Nedd4 protein was
increased 60% when soluble anti-CD3 plus anti-CD28 signal were received, and had a
dramatic increase of 134% when only soluble anti-CD28 antibody was added. Nedd4
protein showed a slightly but not significant increase (27.5%) when T-lymphocytes were
stimulated with plate-bound anti-CD3 antibody only.
Nedd4 mRNA level in activated splenic T-lymphocytes
Change of Nedd4 protein expression can be caused by regulation on translational
level or on transcriptional level as well. Thus, the mRNA level of Nedd4 was
determined at the same time. The results are shown in Figure 2.15. T-lymphocytes
were stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) antibodies,
plate-bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1 µg/ml) antibody for
120 min respectively. As shown in Figure 2.15, Nedd4 mRNA was increased about
20% when soluble anti-CD3 plus anti-CD28 signal were received, and had a larger
increase of 35% when only soluble anti-CD28 antibody was added. Nedd4 mRNA




Findings in this chapter demonstrate that rat splenic T-lymphocytes will down-
regulate Cbl-b expression following perturbation of the CD28 receptor. The mechanism
appears to involve Nedd4, an E3-ubiquitin ligase to degrade the Cbl-b protein in a
proteasomal dependent manner.
To stimulate an effective T-lymphocyte response and subsequent physiological
reaction, both the Ag-specific signal mediated by TCR and the co-stimulatory signal
mediated by CD28 are required [227, 234]. T-lymphocyte proliferation experiments
using cbl-b-/- mice found that CD28-costimulatory is no longer required, suggesting that
there is a closely relationship between Cbl-b protein expression and CD28 signal which
are essential for the full activation of T-lymphocytes [200, 201]. Soluble anti-CD3 plus
anti-CD28 antibodies, plate-bound anti-CD3 alone, or soluble anti-CD28 alone were used
respectively to stimulate T-lymphocyte. The first two stimulation methods generated
similar T-lymphocyte proliferative responses while soluble anti-CD28 alone had no effect
(data not shown). Utilizing plate-bound anti-CD3 alone and soluble anti-CD3 plus anti-
CD28 culture systems allow for the distinguishing between CD3 and CD28 effects under
activation conditions that induce similar proliferation. When young T-lymphocytes
were stimulated with anti-CD3 plus anti-CD28 antibody, and not anti-CD3 alone, there
was a significant reduction in Cbl-b expression. Interestingly, engagement of the CD28
receptor alone can reduce Cbl-b expression to a greater extent than stimulation with CD3
plus CD28. This data confirm that CD3 is not required to down-regulate Cbl-b protein
expression. However, the data do suggest that CD3 signaling pathways may be
involved in influencing the extent to which Cbl-b is down-regulated. Further
experiments will need to be performed to clarify the interaction between the CD3 and
CD28 receptors in regulating Cbl-b expression. Involvement of the Cbl family of
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proteins appears to be somewhat specific since we did not see a significant effect on Cbl
protein expression in stimulated T-lymphocyte. This is consistent with a previous report
showing that Cbl recruitment to the TCR/CD3 complex does not change with age in
activated T-lymphocytes [235]. Also, this supports the conclusion based on cbl-
deficient mice and cbl-b-deficient mice that in T-lymphocyte regulation, Cbl is essential
to the development of thymocyte [198], while Cbl-b is involved in the activation of
peripheral T cell activation [200, 201]
Transcription of cbl-b gene is not altered by any of the stimulatory signals,
suggesting that regulation of Cbl-b is post-transcriptional. This is different from what
was observed in BCR/ABL controlled Cbl-b expression that cbl-b mRNA was down-
regulated by stimulation of the B cell receptors on a B cell line [236]. This indicates
that Cbl-b expression in splenic rat T-lymphocyte is regulated via a signaling pathway
other than what happened in B-lymphocyte.
The tyrosine site at C-terminal of Cbl-b got phosphorylated upon TCR
engagement and phosphorylation further activates Cbl-b’s function to be involved in the
intracellular signaling pathway mediated by TCR signal [188]. However,
phosphorylation of Cbl-b can not determine Cbl-b’s fate to be down-regulated or not.
Since CD3 signal alone or CD28 signal alone induce similar phosphorylation on Cbl-b.
It is not clear whether the phosphorylaiton induced by CD3 signal or CD28 signal are on
different tyrosine site and further experiment are needed to investigate this possibility.
The mechanism by which CD28 down-regulates Cbl-b protein expression appears
to be proteasome dependent in our system since addition of the proteasomal inhibitor
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MG132 and lactacystin blocked Cbl-b down-regulation in young T-lymphocytes. Our
results showing that reduced Cbl-b expression in young rat T-lymphocytes is in a CD28
dependent manner potentially involving proteasome degradation was recently confirmed
by another group in CD28 deficient mice [191]. A recent report showed that CD28
ligation did not down-regulate Cbl-b protein expression [213]. This discrepancy may be
due to the fact that the authors were using a human T-lymphocyte cell line (Jurkat) while
we used primary rat T-lymphocytes. Further support for Cbl-b being down-regulated in
a proteasomal dependent manner was shown in epidermal growth factor (EGF)
stimulated breast cancer cells [221]. The authors showed that stimulating the EGF
receptor with EGF resulted in the proteasomal dependent degradation of Cbl-b, the EGF
receptor itself and several signaling proteins associated with the EGF receptor, while this
paper also showed that Cbl-b expression may be controlled by both proteasome and
lysosome since both proteasome inhibitor and lysosome inhibitor can partially block the
down-regulation of Cbl-b [221]. However, our data showed that lysosome activity is
not required in Cbl-b protein down-regulation because lysosome inhibitor NH4Cl can not
prevent the loss of Cbl-b protein expression under CD3 and CD28 activation.
So far, the detailed mechanism of how Cbl-b being down-regulated is still
unclear. Since the mRNA level of Cbl-b does not change with activation, it is unlikely
that Egr family proteins are involved in the direct regulation of Cbl-b expression. The
Egr proteins are characterized as transcription regulatory factors. They recognize and
bind to a 9-base-pair fragment on the promoter of target genes and induce the
transcription of target genes [237]. Nedd4, but not Itch, is associated with Cbl-b in
splenic rat T-lymphocytes. More Nedd4 are available for association since they are
moving to the same subcellular location as Cbl-b when CD28 receptors on T-
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lymophocytes are stimulated by anti-CD28 antibody. Change of Nedd4 location when
T cells are under different stimulatory circumstance was also observed in mouse D5 TH1
cells, Nedd4 moved from cytoplasm portion to detergent insoluble portion if cells are
induced to anergy [203]. We also found that Nedd4 protein level was higher when
CD28 were activated no matter whether CD3 activation signal was present or not.
Thus, under anti-CD28 antibody treatment, there is a net increase of Nedd4 moving
closer to Cbl-b, and the association between Nedd4 and Cbl-b became stronger when
CD28 is activated. The increased association is achieved by both the enhanced
expression and intracellular translocation of Nedd4 upon CD28 stimulation. As a result,
at the cytoplasm portion (where almost all Cbl-b are expressed), the protein level of
Nedd4 and Cbl-b are reversely related, that is, whenever more Nedd4 were detected,
lower Cbl-b protein level were found at the same time. This phenomenon suggests that
Nedd4 associated with Cbl-b plays its role as an E3 ubiquitin ligase, ubiquitinate Cbl-b
and send them for proteasomal degradation. This is in accordance with the results
showed in 293T human embryonic kidney cell line by Weissman’s group that Nedd4 can
regulate Cbl-b protein level via its E3 ubiquitin ligase activity [220]. Direct evidence of
Nedd4 mediating the down-regulation of Cbl-b in primary rat splenic T-lymphocytes is
unavailable now, since gripNA or siRNA procedure to knockout Nedd4 gene showed low
transfection efficiency in our cell model.
It need to point out that the mRNA level of Nedd4 also changed with CD28
stimulation, which implies some other transcriptional regulation mechanisms are
involved too. The full mechanism about how Nedd4 expression being regulated and
























Figure 2.1 Cbl-b expression under CD3 and CD28 activation
Figure 2.1 Influence of CD3 and CD28 activation on Cbl-b protein expression in young
splenic T-lymphocyte. Splenic T-lymphocytes were isolated from young (6 mo) rats.
T-lymphocytes were activated with soluble anti-CD3 plus anti-CD28 antibodies for 0, 30,
60, and 120 min. Total cellular proteins were extracted and western immunoblotting
performed as described in the Materials and Methods. Values are the mean ± S.E.M. of
four individual rats calculated from the densitometric analysis of the autoradiograms.
An (*) indicates significantly different (P<0.05) and (**) indicates significantly different




















Figure 2.2 Cbl-b expression under CD3 activation
Figure 2.2 Influence of CD3 activation on Cbl-b protein expression in young splenic T-
lymphocyte. Splenic T-lymphocytes were isolated from young (6 mo) rats. T-
lymphocytes were activated with plate-bound anti-CD3 antibody for 0, 30, 60, and 120
min. Total cellular proteins were extracted and western immunoblotting performed as
described in the Materials and Methods. Values are the mean ± S.E.M. of four























Figure 2.3 Cbl-b expression under CD28 treatment
Figure 2.3 Influence of CD28 treatment on Cbl-b protein expression in young splenic T-
lymphocyte. Splenic T-lymphocytes were isolated from young (6 mo) rats. T-
lymphocytes were activated with anti-CD28 antibody for 0, 30, 60, and 120 min. Total
cellular proteins were extracted and western immunoblotting performed as described in
the Materials and Methods. Values are the mean ± S.E.M. of four individual rats
calculated from the densitometric analysis of the autoradiograms. An (**) indicates
significantly different (P<0.01) when comparing treated with untreated T-lymphocytes.
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Figure 2.4 Cbl-b expression under CTLA-4 treatment
Figure 2.4 Influence of CTLA-4 treatment on Cbl-b protein expression in young splenic
T-lymphocyte. Splenic T-lymphocytes were isolated from young (6 mo) rats. T-
lymphocytes were activated with anti-CTLA-4 antibody for 0, 30, 60, and 120 min.
Total cellular proteins were extracted and western immunoblotting performed as
described in the Materials and Methods. Values are the mean ± S.E.M. of four
individual rats calculated from the densitometric analysis of the autoradiograms. An
(**) indicates significantly different (P<0.01) when comparing treated with untreated T-
lymphocytes.











































Figure 2.5 Cbl-b mRNA expression in activated splenic T-lymphocytes
Figure 2.5 Influence of different stimulatory signals on Cbl-b mRNA expression in young
splenic T-lymphocyte. Splenic T-lymphocytes were isolated from young (6 mo) rats.
T-lymphocytes were activated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml)
antibodies, plate-bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1 µg/ml)
antibody for 120 min. Total cellular RNA were extracted and RT-PCR performed as
described in the Materials and Methods. Values are the mean ± S.E.M. of four




















Figure 2.6 Cbl-b expression under MG132 treatment
Figure 2.6 Impact of proteasomal inhibition on Cbl-b expression in young splenic T-
lymphocytes. Young (6 mo) splenic T-lymphocytes were isolated and stimulated with
soluble anti-CD3 plus anti-CD28 as described in Figure 2.1 legend. The proteasomal
inhibitor MG132 was added simultaneously with the antibodies. T-lymphocytes were
cultured for 0, 30, 60 and 120 min then total cellular proteins were extracted and western
immunoblotting performed as described in the Materials and Methods. Values are the





















Figure 2.7 Cbl-b expression under Lactacystin treatment
Figure 2.7 Impact of proteasomal inhibition on Cbl-b expression in young splenic T-
lymphocytes. Young (6 mo) splenic T-lymphocytes were isolated and stimulated with
soluble anti-CD3 plus anti-CD28 as described in Figure 2.1 legend. The proteasomal
inhibitor Lactacystin was added simultaneously with the antibodies. T-lymphocytes
were cultured for 0, 30, 60 and 120 min then total cellular proteins were extracted and
western immunoblotting performed as described in the Materials and Methods. Values
are the mean ± SEM of 4 individual rats calculated from the densitometric analysis of the
autoradiograms.
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Figure 2.8 Cbl-b expression under NH4Cl treatment
Figure 2.8 Impact of lysosome inhibition on Cbl-b expression in young splenic T-
lymphocytes. Young (6 mo) splenic T-lymphocytes were isolated and stimulated with
soluble anti-CD3 plus anti-CD28 as described in Figure 2.1 legend. The proteasomal
inhibitor NH4Cl was added simultaneously with the antibodies. T-lymphocytes were
cultured for 0, 30, 60 and 120 min then total cellular proteins were extracted and western
immunoblotting performed as described in the Materials and Methods. Values are the
mean ± SEM of 4 individual rats calculated from the densitometric analysis of the
autoradiograms. An (*) indicates significantly different (P<0.05) when comparing
stimulated with unstimulated T-lymphocytes.


















Figure 2.9 Proteasome activity in splenic T-lymphocytes
Figure 2.9 Influence of different stimulatory signals on proteasome activity in young
splenic T-lymphocyte. Splenic T-lymphocytes were isolated from young (6 mo) rats.
T-lymphocytes were stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1
µg/ml) antibodies, plate-bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1
µg/ml) antibody for 120 min. Total cellular proteins were extracted and proteasome
activities determined as described in the Materials and Methods. Values are the mean ±


























Figure 2.10 Tyrosine phosphorylation of Cbl-b in splenic T-lymphocytes
Figure 2.10 Tyrosine phosphorylation of Cbl-b in young splenic T-lymphocyte. Splenic
T-lymphocytes were isolated from young (6 mo) rats. T-lymphocytes were stimulated
by plate-bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1 µg/ml) antibody
for 0, 5, 30, and 120 min. Total cellular proteins were extracted and
immunoprecipitated by anti-Cbl-b antibody, tyrosine phosphorylation of Cbl-b was
determined as described in the Materials and Methods.
64
Figure 2.11 Association of Nedd4/Itch with Cbl-b 
 
Figure 2.11 Association of Nedd4/Itch with Cbl-b in young splenic T-lymphocyte.
Splenic T-lymphocytes were isolated from young (6 mo) rats. T-lymphocytes were
stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) antibodies, plate-
bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1 µg/ml) antibody for 120
min. Total cellular proteins were extracted and immunoprecipitated with anti-Cbl-b
antibody. Western immunoblotting was performed as described in the Materials and
Methods.
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Figure 2.12 Subcellular localization of Nedd4 and Cbl-b in young splenic T-lymphocyte.
Splenic T-lymphocytes were isolated from young (6 mo) rats. T-lymphocytes were
unstimulated (A) or stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml)
antibodies (B), plate-bound anti-CD3 (10 µg/ml) antibody (C), or soluble anti-CD28 (1
µg/ml) antibody (D) for 120 min. Total cellular proteins were extracted and small scale
sucrose density gradient centrifugation followed by western immunoblotting (left) was
performed as described in the Materials and Methods. Pie (right) values show Nedd4
expression in lane 2 and 3 (red) vs. lane 4 to 6 (white) that are calculated from the
densitometric analysis of the autoradiograms.
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Figure 2.13 Cbl-b and Nedd4 expression in cytoplasm
Figure 2.13 Cytoplasm expressions of Cbl-b and Nedd4 in young splenic T-lymphocyte.
Splenic T-lymphocytes were isolated from young (6 mo) rats. T-lymphocytes were
unstimulated or stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml)
antibodies, plate-bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1 µg/ml)
antibody for 120 min. Cytoplasm proteins were extracted and western immunoblotting





























Figure 2.14 Nedd4 expression under different stimulatory condition
Figure 2.14 Nedd4 expressions in young splenic T-lymphocyte. Splenic T-lymphocytes
were isolated from young (6 mo) rats. T-lymphocytes were unstimulated or stimulated
by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) antibodies, plate-bound anti-
CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1 µg/ml) antibody for 120 min. Total
cellular proteins were extracted and western immunoblotting performed as described in
the Materials and Methods. Values are the mean ± S.E.M. of four individual rats
calculated from the densitometric analysis of the autoradiograms. An (*) indicates






























Figure 2.15 Nedd4 mRNA level under different stimulatory condition
Figure 2.15 Nedd4 mRNA expressions in young splenic T-lymphocyte. Splenic T-
lymphocytes were isolated from young (6 mo) rats. T-lymphocytes were unstimulated
or stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) antibodies, plate-
bound anti-CD3 (10 µg/ml) antibody, or soluble anti-CD28 (1 µg/ml) antibody for 120
min. Total cellular RNA were extracted and RT-PCR performed as described in the
Materials and Methods. Values are the mean ± S.E.M. of four individual rats calculated
from the densitometric analysis of the autoradiograms. An (*) indicates significantly
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different (P<0.05) and (**) indicates significantly different (P<0.01) when comparing
with soluble anti-CD28 stimulated T-lymphocytes.
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Chapter 3: Proteasome-dependent Cbl-b Down-regulation does not
occur in Aged T-lymphocyte
3.1 ABSTRACT
We have showed that there is a proteasome-dependent down-regulation of Cbl-b
with CD28 activation in young splenic T-lymphocytes. Since decreased ubiquitin-
proteasome system function is found to be causally related to aging associated
malfunction, we studied the actual expression and function of Cbl-b in aged T-
lymphocytes. We found in aged T-lymphocyte the CD28-dependent Cbl-b down-
regulation did not occur. We also showed that Cbl-b was still functional and its
expression was strongly associated with reduced T-lymphocyte proliferation. Such age
effect on Cbl-b regulation was not caused by reduced CD28 receptor expression, or
increased CTLA-4 expression. Association of Cbl-b and Nedd4 seems to be normal too.
Decline in proteasome activity are observed and may be responsible for the dysregulation
of Cbl-b in aging. These data indicate Cbl-b level along with proteasome activity are
important for T-lymphocyte activation in aging.
3.2 INTRODUCTION
Previous aging research has been focused on decreases in positive
signals/regulators/effectors that result in less effective response of aged cells to stimuli.
Normally those stimuli can induce optimal reaction in young cells. However, in aging
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process, negative signals/regulators/effectors are as important as their positive peers.
The up-regulation of negative signal would also lead to decreased cell activity.
CTLA-4 (cytotoxic T-lymphocyte antigen-4) is probably one of the most well-
known T cell negative regulators. CTLA-4 is similar to CD28 in their extracellular
structure. They all express a conserved amino acid motif, MYPPPY, on their
extracellular domain [238]. So CD28 and CTLA-4 bind to the same ligands expressed
on APCs--CD80 and CD86. However, the functional outcomes of binding with CD28
or CTLA-4 are opposite. Interaction of CD80/CD86 with CD28 provides costimulatory
signal to boost T cell response, while engagement of CTLA-4 with CD80/CD86 will
inhibit the T cell activation and proliferation by competing with CD28 for ligands and
“turning off” the ongoing cell division [239]. A functional balance between CD28 and
CTLA-4 is reached and cell proliferation is tightly regulated. The percentage and
relative intensity of both CD28 and CTLA-4 change with age. The difference is CD28
expression decreases while CTLA-4 level increases. Since affinity of CTLA-4-
CD80/CD86 ligation is 20-100-fold higher than CD28 ligation [240], up-regulation of
CTLA-4 with aging has more profound suppressive impact on T cell function. Thus, T
cell senescence is the result of both diminished positive signal and elevated negative
signal.
Up-regulation of negative signal in aging that leads to functional loss in immune
system is not limited to T cells. In aged mouse macrophage, Toll-like receptor-
signaling pathway is down-regulated because the negative regulator of this pathway, IL-1
receptor-associated kinase 3 is increased with age. Directly, such change will cause the
dysregulation in cytokine secretion and indirectly, lead to poor production of antibodies
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[241]. In old activated B cells, immunoglobulin class switch recombination (CSR) is
impaired due to the increase of a negative regulator, Id2. Id2 negatively regulates
transcription factor E47, and E47 is required for CSR. Thus, the antibody class
diversity in old activated B cells is decreased and the effector function of antibodies to
fight the same antigen dramatically reduced [112]. Increased negative signal is also
involved in the age-associated thymus involution. TCR β-rearrangement requires the
expression of E2A, a transcription regulator. E2A activity is negatively regulated by
LMO2, whose expression increases more than 5 times with age [242].
As a negative regulator to early T cell activation events, whether Cbl-b’s
expression would also be up-regulated with age and whether increased Cbl-b would be
able to more effectively inhibit aged T cell signaling pathways are still unknown. Cbl is
a close family member of Cbl-b and shares a lot of similarity with Cbl-b in both structure
and function. In old mice, P-glycoproteinhigh CD4 memory cells show low proliferative
activity, meanwhile, the proportion of Cbl translocated to immune synapse increased with
age, which suggests that Cbl in immune synapse is responsible for the anergy of P-gphigh
CD4 memory cell subset [33].
Based on these observations, in this chapter, we will test whether Cbl-b’s
expression will change with age, and if such change is correlated with T cell activity
change such as proliferation. Also, the mechanism of how this would happen will also
be studied in this chapter.
3.3 MATERIALS AND METHODS
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Materials
Anti-Cbl-b antibody (G-1), anti-Cbl antibody (C-15), and anti-β-actin (I-19) were
purchased from Santa Cruz (Santa Cruz, CA). Anti-CD3 (G4.18) and anti-CD28
(JJ319) monoclonal antibodies, anti-CD4 (OX-35) FITC labeled and anti-CD8 (OX-8)
PE labeled antibodies were purchased from BD PharMingen (San Jose, CA). All cell
culture media were purchased from Mediatech (Herndon, VA) and all other chemicals
were reagent grade or higher and from Sigma-Aldrich (St. Louis, MO).
Animals
Male, 4-6-month (young) and 18-20-month (old) Sprague-Dawley rats were
purchased from Harlan Sprague Dawley (Indianapolis, IN) and maintained on a 12 hour
light/dark cycle and standard chow diet. All animal procedures were approved by the
University of Texas Animal Use and Care Committee.
T-lymphocyte isolation and culture
Rats were sacrificed and spleens aseptically removed. Single splenic cell
suspensions were isolated by homogenization and filtering through a 25mm syringe filter.
Lymphocytes were isolated via differential migration following centrifugation in
Lymphocyte Separation Medium (Mediatech, Herndon, VA). T-lymphocytes were
isolated using negative selection Immulan columns (Biotecx, Houston, TX) per
manufacturer’s instructions as previously described [230]. T-lymphocytes were counted
using the Cell-Dyn 900 Hematology Analyzer (Sequoia-Turner, Mountainview, CA).
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T-lymphocytes, 2.5x107 cells per petri dish, were stimulated at 37ºC for designated time
in pre-warmed complete culture media (RPMI 1640 supplemented with 10% heat
inactivated fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 mM 2-
mercaptoethanol, 2 mM L-glutamine and 25 mM HEPES buffer) with 10 µg/ml anti-CD3
plus 1 µg/ml anti-CD28 antibodies, 10 µg/ml plate-bound anti-CD3, 1 µg/ml anti-CD28
antibody only, or 5 µg/ml anti-CTLA-4 antibody.
T-lymphocyte proliferation
T-lymphocyte proliferation was determined by MTT cell proliferation assay
(ATCC, Manassas, VA). Briefly, 2x105 splenic T-lymphocytes (2x106 cells/ml) were
plated in each well and cultured at 37ºC with complete media in the presence or absence
of 10 µg/ml anti-CD3 and 1 µg/ml anti-CD28 for 48 hr. 10 µl MTT reagent was added
and continued incubating for 4 hr at 37ºC until purple precipitates were visible. After
that, 100 µl detergent reagent was added, plates were then left at room temperature in the
dark for 2 hr and absorbance was recorded at 550nm. T-lymphocytes for each treatment
were plated out in triplicate and average was used for data calculation.
Western immunoblotting
Cellular protein was isolated and western immunoblotting performed as
previously described [231]. Briefly, total protein from stimulated or unstimulated T-
lymphocytes were pelleted and lysed in 50 µl of lysis buffer containing 50 mM Tris (pH
7.4), 10 mM EDTA, 150 mM NaCl, 0.1% Tween 20, 1 µl/ml β-ME, and 7 µl/ml protease
inhibitor mix. Lyastes were centrifuged and the protein containing supernatant was
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quantitated using the Bio-Rad protein assay (Bio-Rad, Hercules, CA). 30 µg of total
protein was separated by SDS-PAGE along with Bio-Rad’s Kaleidoscope Prestained
Standards. The protein was transferred onto PolyScreen PVDF membranes (NEN Life
Sciences, Boston, MA) and the membranes blocked with 15 ml blocking solution
containing 25 mM Tris (pH 8.0), 125 mM NaCl, 4% non-fat milk, and 0.1% Tween 20
prior to probing with anti-Cbl-b antibody (1:3000 dilution in 15 ml blocking solution),
anti-Nedd4 or anti-PI3K p85 antibody. Immunoreactive bands were detected using an
alkaline phosphatase-conjugated goat-anti-rabbit secondary antibody and CDP-Star
chemiluminescence reagent (NEN Life Sciences, Boston, MA). Densitometry was
performed using a BioRad Gel Documentation System. The membrane was also probed
with an anti-β-actin antibody to control for lane loading variation.
Flow cytometric analysis
Expression of the CD28 or CTLA-4 receptor on CD4+ and CD8+ T-lymphocytes
was determined as we previously described [243, 244]. Splenic T-lymphocytes were
stimulated as described before. 1 x 106 T-lymphocytes were treated with 200 µl 1X
RBC Lysis buffer (eBioscience, San Diego, CA) for 2 minutes to lyse any remaining red
blood cells that might interfere with analysis. Lysis was ceased with the addition of 5ml
PBS and centrifugation at 250 g for 5 min. Cell pellets were incubated with PE labeled
anti-CD28 or anti-CTLA-4 antibody plus FITC labeled anti-CD3, anti-CD4, or anti-CD8
antibody. Excess antibodies were removed by washing with PBS with 0.1% NaN3 and
cells were fixed in 0.5% paraformaldehyde in PBS. CD28 or CTLA-4 receptor
expression on T-lymphocyte subsets was analyzed using a BD FACScaliber flow
cytometer and CellQuest Pro software (BD Pharmingen, San Diego, CA).
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Immunoprecipitation of Cbl-b
Stimulated or unstimulated T-lymphocytes from 4 rats were pooled together.
Pooled T-lymphocytes were pelleted and total protein lysed in 500 µl of lysis buffer
containing 50 mM Tris (pH 7.4), 10 mM EDTA, 150 mM NaCl, 0.1% Tween 20, 1 µl/ml
β-ME, and 7 µl/ml protease inhibitor mix. Lyastes were centrifuged and the protein
containing supernatant were pre-cleared by adding 40 µl of protein A/G plus agarose
(Upstate, Charlottesville, VA) and rotated at 4ºC for 1 hr. The mixture was pelleted at
2,000 g for 2 min at 4ºC and supernatant was quantitated using the Bio-Rad protein assay
(Bio-Rad, Hercules, CA). 500 µg of total protein were incubated with 4 µg anti-Cbl-b
antibody (H-454) and rotated overnight at 4ºC. Protein A/G plus agarose (20 µl) was
added and the mixture was rotated again at 4ºC for 2 hr. The mixture was pelleted at
2,000 g for 2 min at 4ºC and the beads washed 3 times with 500 µl lysis buffer. The
bead slurry was suspended in 2X Laemmli sample buffer, boiled for 10 min and the
supernatant (immunoprecipitated protein) was collected.
20S proteasome activity assay
Proteasome activity is determined by CHEMICON 20S Proteasome Activity
Assay Kit (Chemicon, Temecula, CA) via manufacturer’s instruction. Briefly, total T
cell protein is isolated as described before and protein concentration determined. 1 mg
of total protein and 5 nM proteasome substrate (Suc-LLVY-AMC) are incubated in 25
mM HEPES (pH 7.5), 0.5 mM EDTA, 0.05% NP-40, and 0.001%SDS in 96-well
fluorometer plate (100 µl total volume) for 1 hr at 37ºC. In parallel, AMC standard
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curve from 0.04 mM to 12.5 mM and proteasome positive control curve (1:4 to 1:256)
are prepared. Fluorescences are recorded in DTX 880 Multimode Detector (Beckman,
Fullerton, CA) with 380/460 nm filter.
Statistical analysis
Data from young and old T-lymphocytes stimulation experiments were analyzed 
by two-way ANOVA, the significance of the interaction between the age factor and 
stimulation factor was determined with Minitab software (State College, PA).  Other 
data were analyzed by one-way ANOVA and statistical difference were determined using 
Tukey’s multiple comparison test with GraphPad Prism software (San Diego, CA).  A 
p<0.05 was considered significantly different. 
3.4 RESULTS
Influence of aging on Cbl-b expression in activated T-lymphocytes
The data in Chapter 2 shows that anti-CD28 stimulation is required to observe a
significant reduction in Cbl-b expression in young T-lymphocytes. Therefore, young
and old splenic T-lymphocytes were stimulated with soluble anti-CD3 plus anti-CD28
antibodies for 120 min and Cbl-b expression measured (Fig 3.1). Activation
significantly (P<0.01) reduced Cbl-b expression by approximately 40% in the young T-
lymphocytes, but did not change Cbl-b expression significantly in aged splenic T-
lymphocytes.
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T-lymphocyte proliferation in young and old rat
To confirm that the anti-CD3 plus anti-CD28 stimulation used herein induced T-
lymphocyte proliferation and the effective T-lymphocyte proliferation is parallel with
reduced Cbl-b expression, the proliferative response in young and old splenic T-
lymphocytes was determined. Fig 3.2 shows that anti-CD3 plus anti-CD28 stimulation
increased T-lymphocyte proliferation 4.6 times in young splenic T-lymphocytes and 3.5
times in old ones and aging resulted in approximately a 35% reduction in the proliferative
response.
Influence of aging on Cbl-b function in stimulated T-lymphocytes
As shown in Fig 3.1 and Fig 3.2, the Cbl-b expression remains unchanged upon
anti-CD3 plus anti-CD28 stimulation in old T-lymphocytes and old T-lymphocytes fail to
proliferate properly as young T-lymphocytes. One of Cbl-b’s functions is to set the
activation threshold of T-lymphocytes, suggesting that low proliferation in old T-
lymphocytes is probably caused by sustained Cbl-b expression after stimulation. To
prove that, function of Cbl-b in stimulated old T-lymphocytes is first determined.
Binding of Cbl-b protein with its target, PI3K and the ubiquitination of PI3K (data not
shown) are tested. Fig 3.3 shows that in old T-lymphocytes, Cbl-b is still able to bind
with p85 subunit of PI3K when stimulated by anti-CD3 and anti-CD28 antibodies.
Influence of aging on Nedd4-Cbl-b association in stimulated T-lymphocytes
79
In old T-lymphocytes, why stimulation from both CD3 and CD28 fail to down-
regulate Cbl-b is still unclear. According to the mechanisms of Cbl-b being regulated in
young T-lymphocytes upon stimulation, we are trying to find out the reason causing the
dys-regulation of Cbl-b with age.
In transfected 293T cell line, as a HECT E3 ubiquitin ligase, Nedd4 degrades
Cbl-b expression via the WW domain [220]. In previous research, we also proved that
expression of Nedd4 and its association with Cbl-b was strongly related with the
expression change of Cbl-b upon CD28 stimulation, indicating that Nedd4 is responsible
for the down-regulation of Cbl-b. Thus, continuous association of Nedd4 with Cbl-b in
old rat T-lymphocytes was tested. As shown in Fig 3.4, association of Nedd4 with Cbl-
b does not change with age and the extent of such association under CD3 and CD28
activation is comparable in young and old T-lymphocytes with a minor increase with age.
CD28 and CTLA-4 receptor expression in young and old rat
In young rat splenic T-lymphocytes, signals from CD28 or CTLA-4 receptors are
required to regulate Cbl-b expression. Meanwhile, short of CD28 costimulatory
receptor expression are found in both CD4+ and CD8+ T cell subset with aging [68, 245].
Thus, CD28 levels in CD3+, CD4+, and CD8+ T-lymphocytes were examined. Fig 3.5
shows that CD28 receptor expression was not significantly influenced by age in T-
lymphocytes.
Since up-regulation of CTLA-4 expression was also reported in aged human CD4+
T cells [246], the expression of CTLA-4 in CD4+, and CD8+ T-lymphocytes before and
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after CD3 plus CD28 stimulation were examined. The results are shown in Fig 3.6.
There was no obvious effect of age on CTLA-4 induction in either CD4+ or CD8+ T-
lymphocytes.
Proteasome activity in young and old rat
It has been proven that in young splenic T-lymphocytes, Cbl-b is down-regulated
in proteasome. However, the aging process is associated with the proteasome
inactivation which may in turn weaken the ability of aged T-lymphcytes to down-regulate
Cbl-b. Proteasome activities in T-lymphocytes isolated from young and old rats were
determined. The results are shown in Figure 3.7. The 20S proteasome activity in old
T-lymphocytes is much lower than that in young ones, only 45% of proteasome activity
is detected in old T-lymphocytes compared to in the young T-lymphocytes.
Ubiquitination of Cbl-b in young and old rat
In order to make sure the decreased proteasome activity observed in old rat T-
lymphocytes is caused by malfunction of proteasome itself or is the result of other
failures in ubiquitin system upstream of proteasome, the ubiquitination of Cbl-b in young
and old T-lymphocytes before and after stimulation are tested by immunoprecipitation.
The results are shown in Figure 3.8. In young rat splenic T-lymphocytes, the relative
ubiquitination level of Cbl-b protein slightly decreased after CD3 and CD28 stimulation,
while in old T-lymphocytes, ubiquitination of Cbl-b increased upon activation indicating
ubiquitinated Cbl-b accumulated in the old T-lymphocyte.
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3.5 DISCUSSION
It is well known that aging results in reduced T-lymphocyte proliferation ex vivo
[247]. To date, attention has focused on understanding the impact of aging on receptor-
mediated signal transduction pathways leading to up-regulation of the proliferative
response [65, 248]. The data presented here, for the first time, show that aged splenic
T-lymphocytes fail to down-regulate Cbl-b expression following perturbation of the
CD28 receptor. The mechanism appears to involve the low activity of proteasome in
aged T-lymphocytes to degrade the Cbl-b protein in a proteasomal dependent manner.
Soluble anti-CD3 plus anti-CD28 antibody can not effectively induce T-
lymphocyte proliferation isolated from old rat spleen. Meanwhile, the same soluble
anti-CD3 plus anti-CD28 stimulation condition in old T-lymphocytes fail to reduce Cbl-b
expression as what happened in young T-lymphocyte. Related to the fact that T cells
with no Cbl-b expression can proliferate much better that T cells with normal Cbl-b
expression [200, 201]. Results in this chapter show that, in young peripheral T-
lymphocytes, stimulating signals received by T-lymphocytes lead to cell proliferation and
IL-2 secretion after Cbl-b protein is first down-regulated, thus, higher Cbl-b expression
sets a higher threshold for the activation and proliferation of aged T-lymphocytes.
Functional studies of Cbl-b showed that in aged T-lymphocyte, after CD3 and CD28
stimulation, the remaining Cbl-b kept its ability to bind with the p85 subunit of PI3K.
No established experiments are available to directly test the function of Cbl-b in
stimulated T-lymphocytes. One of the consequences of p85 being mono-ubiquitinated
by Cbl-b is PI3K unable to recruit to CD28 receptor [213] and thus its p110 subunit can
not be fully activated. Since PI3K activation is important to T cell proliferation and
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function [249], data show here strongly supports the idea that Cbl-b is still functional in
old T-lymphocyte and sets a higher activation threshold for aged old T-lymphocytes.
The mechanism does not appear to involve the age-dependent changes in the
relative proportions of CD28 receptor or CTLA-4 expression in T-lymphocytes.
However, this does not rule out the possibility that altered CD28/CTLA-4 expression
may take place in other immune organs and/or in other animal models [66]. Age-related
deficiency of CD28 expression in T cells and its influence on T cell activity have been
studied. However, the results are inconsistent. In human peripheral blood T cells,
decline of CD28 expression are found to be more dramatically in CD8+ T cells [67].
The appearance and percentage of CD8+CD28null T cells in aged individuals are reversely
correlated to antibody production in response to vaccine [250, 251], length of telomeres
[252], and are considered as a valuable bio-marker of immunocompromision and
replicative senescence in human aging. In contrast to that, CD4+CD28null T cells
accumulated in older individuals are functional and long-lived, and probably account for
the generation of autoreactive B cells [253, 254]. Changes of CD28 expression with age
in mice are different. In C57BL/6 mice, CD28 does not decline in their whole lifespan.
There are no age difference in CD28 expression on resting T cells and a significant
slower CD28 induction in old stimulated T cells [255]. In DBA/2 mice, percentage of
CD28 positive in splenic T cells are slightly increased with age and the increas is
statistically significant in CD8+ subset, but the CD28 expression do not change in either
subsets in blood peripheral T cells [256]. A unique CD8+CD28high subset are found in
old mice with immune regulation function [257]. All of these data suggest that co-
stimulatory function of CD28 signal system in T cell senescence of human are different
from its role in rodents T cells aging. In our studies, we showed CD28 signal could
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down-regulate Cbl-b expression and enhance T cell activity, but failed to do so in aging.
We also showed that CD28 expression in rat splenic T cells did not change with age and
was not responsible for the incompetence to stimulate Cbl-b protein degradation. This
observation excludes the possibility that human-mouse difference in age-related decline
in CD28 expression will exert distinctive regulation mechanism on Cbl-b and indicates
human and rodent may share the same regulatory pathway to control Cbl-b expression in
aging. Thus, aged rat and mouse will be good models to further study the dysregulation
of Cbl-b and immune senescence caused by high Cbl-b level.
The association between Cbl-b and Nedd4, the possible regulator of Cbl-b,
remained the same in old activated T-lymphocytes, indicating the CD28-signal-induced
intracellular movement of Nedd4 and its association with Cbl-b is intact with age.
It seems that it is the proteasome activity that determines the extent and rate of
Cbl-b’s down-regulation in old T-lymphocytes. In accordance with the low proteasome
activity in old T-lymphocyte, the total ubiquitinated protein is accumulated in aged T-
lymphocytes (data not shown) which is also true if only examining the ubiquitination
level of Cbl-b protein. This also means age does not have any dramatic influence on the
ubiquitination process in T-lymphocytes and indirectly proves that the function of Nedd4
to add ubiquitin tag on Cbl-b for proteasome degradation is unaffected by age too.
Declined proteasome activity with aging have been reported previously [154] with
various reasons, including reduced expression of proteasome subunits [258, 259], post-
translational modification of proteasome subunits [260], and accumulation of inhibitory
damaged proteins such as oxidized [158], HNE-modified [261], or ubiquitinated [262]
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proteins. Whether all or part of the factors listed above and which factors lead to
dysregulation of proteasome activity in this particular case is still unclear. Thus,
detailed experiments on the proteasome system in old rat splenic T-lymphocytes are
required to find out the ultimate reason that cause the accumulation of Cbl-b with age and





















Figure 3.1 Cbl-b expression in young and old splenic T-lymphocytes
Figure 3.1 Influence of age on Cbl-b protein expression in activated T-lymphocytes.  
Splenic T-lymphocytes were isolated from young (6 mo) and old (18 mo) rats as 
described in the Materials and Methods.  T-lymphocytes were isolated and stimulated 
with soluble anti-CD3 plus anti-CD28 for 120 min as described in the Materials and 
Methods.  Total cellular protein extraction and western immunoblotting were performed 
as described in the Materials and Methods.  Values are the mean ± SEM of 9 individual 
rats calculated from the densitometric analysis of the autoradiograms.  An ‘**’ indicates 
significantly different (p<0.01) when the interaction between age and stimulation factors 



















Figure 3.2 T cell proliferation in young and old rats
Figure 3.2 Influence of aging on splenic T-lymphocyte proliferation.  Splenic T-
lymphocytes were isolated from young (6 mo) and old (18 mo) rats as described in the 
Materials and Methods then activated with soluble anti-CD3 and anti–CD28 antibodies 
for 48 hours and proliferation determined using the MTT dye uptake assay as described 
in the Materials and Methods.  Data are expressed as the absorbance at 570 nm.  
Values are the mean ± SEM of 3 individual rats.  An ‘*’ indicates significantly different 
(p<0.05) when comparing the young and old anti-CD3 plus anti-CD28 stimulated group.   
 
87
Figure 3.3 Ubiquitination of PI3K by Cbl-b in splenic T-lymphocytes
Figure 3.3 Ubiquitination of PI3K by Cbl-b in young and old splenic T-lymphocytes.  
Splenic T-lymphocytes were isolated from young (6 mo) and old (18 mo) rats.  T-
lymphocytes were stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) 
antibodies for 120 min.  Total cellular proteins were extracted and immunoprecipitated 
with anti-Cbl-b antibody.  Western immunoblotting was performed as described in the 
Materials and Methods.   
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Figure 3.4 Nedd4-Cbl-b associations in young and old stimulated T-lymphocytes
Figure 3.4 Nedd4-Cbl-b associations in young and old stimulated splenic T-lymphocytes.  
Splenic T-lymphocytes were isolated from young (6 mo) and old (18 mo) rats.  T-
lymphocytes were stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) 
antibodies for 120 min.  Total cellular proteins were extracted and immunoprecipitated 
with anti-Cbl-b antibody.  Western immunoblotting was performed as described in the 


















Figure 3.5 CD28 expression in young and old splenic T-lymphocytes
Fig 3.5 Affect of aging on CD28 receptor expression in T-lymphocytes.  Splenic T-
lymphocytes were isolated from young (6 mo) and old (18 mo) rats as described in the 
Materials and Methods.  CD28 receptor expression was determined by flow cytometry 
as described in the Materials and Methods.  Data are expressed as the percent CD28 
receptor positive cells within the CD3+, CD4+, or CD8+ T-lymphocyte population. Values 




































Figure 3.6 CTLA-4 expression in young and old splenic T-lymphocytes
A.
B.
Fig 3.6 Affect of aging on CTLA-4 expression in T-lymphocytes.  Splenic T-
lymphocytes were isolated from young (6 mo) and old (18 mo) rats and stimulated with 
soluble anti-CD3 and anti–CD28 antibodies for 2 hours as described in the Materials and 
Methods.  CTLA-4 expression was determined by flow cytometry as described in the 
Materials and Methods.  Data are expressed as the percent CTLA-4 receptor positive 
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cells within the CD4+, or CD8+ T-lymphocyte population. Values are the mean ± S.E.M. 
of 4 individual rats. 
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Figure 3.7 Proteasome activity in young and old splenic T-lymphocytes
Figure 3.7 Proteasome activity in young and old splenic T-lymphocytes.  Splenic T-
lymphocytes were isolated from young (6 mo) and old (18 mo) rats.  Total cellular 
proteins were extracted and proteasome activities determined as described in the 
Materials and Methods.  Values are the mean ± S.E.M. of four individual rats calculated 
from the densitometric analysis of the autoradiograms.  An ‘**’ indicates significantly 
























Figure 3.8 Ubiquitination of Cbl-b in young and old splenic T-lymphocytes
Figure 3.8 Ubiquitination of Cbl-b in young and old splenic T-lymphocytes.  Splenic T-
lymphocytes were isolated from young (6 mo) and old (18 mo) rats.  T-lymphocytes 
were stimulated by soluble anti-CD3 (10 µg/ml) plus anti-CD28 (1 µg/ml) antibodies for 
120 min.  Total cellular proteins were extracted and immunoprecipitated with anti-Cbl-b 
antibody.  Western immunoblotting was performed as described in the Materials and 
Methods. 
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Chapter 4: Cbl-b Deficiency Partially Reverse T-lymphocytes
Function Lost in Aging
4.1 ABSTRACT
In previous studies, we demonstrated that old rat splenice T-lymphocytes fail to
down-regulation Cbl-b expression upon CD28 stimulation which is associated with
reduced T-lymphocyte proliferation. This suggests that high levels of Cbl-b expression
prevent T-lymphocyte activation in aged T-lymphocytes. There is evidence suggesting
that deficiency of Cbl-b protein can greatly increase the T-lymphocyte activity.
However, whether lack of Cbl-b protein during aging process could reverse the loss of T-
lymphocyte proliferation and prevent the immunesenescence. We compared the
immune system function between Cbl-b knock-out (KO) mice and wild-type (WT) mice
at young and old age. Our results showed that old Cbl-b KO T-lymphocytes
demonstrate same proliferation ability as young WT T-lymphocytes. T-lymphocytes
from old Cbl-b KO mice also showed less spleen enlargement, decrease in CD4/CD8
ratio, and less amount of suppressive regulatory T-lymphocytes. Taken together, these
data indicate that deficiency of Cbl-b in old mice slow down the aging process and down-
regulation of Cbl-b might replenish the immune function in the old.
4.2 INTRODUCTION
Dysregulation of the immune system is probably one of the biggest problems that
threaten the elder’s health. The immune system is a quite complicated network
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composed of a variety of cell types. Functional change in one cell type may greatly
affect other cell types’ function and development. Due to this feature, the work to find
out the key component that causes immunosenescence is not easy since in aged immune
system, multiple changes have been reported in different immune cell types at different
immune system developing stages.
Although there are controversial results concerning the changes happened in aged
immune system [12], other studies showed quite consistent transformation in the
phenotype of immune system along with advanced age. First, a phenomenon termed
“thymic involution” is observed in several species [263-266]. The thymic output of
naïve T cell to peripheral T cell pool decreases with age, which is characterized by less
weight in thymus, reduced DN1 thymocytes and increased DN3 thymocytes in thymus
from aged model. Although the naïve T cell input from thymus decrease with age, the
size of entire peripheral T cell pool does not change accordingly. This is because T cell
homeostasis plays its role to make up the T cell number loss from naïve T cells by
increasing the proliferation of T cells already in the peripheral pool [267] and reducing
the activation-induced cell death [268]. As a result, the subpopulation composition
within T cell repertoire changed with advanced age. Proportion of CD8+ T cells
increase due to the clonal expansion [269]. More memory T cell subsets are observed in
both CD4+ and CD8+ aged T cells [270]. Also associated with aging is the higher
expression of P-glycoprotein, a membraneous efflux pump, in both T cell subsets [271].
Besides the subpopulation change with age, old T cells become less responsive to
extracellular stimulation because the initial steps of T cell activation are defective. T
cells express less CD28, the costimulatory molecule of T cell activation and more CTLA-
4, the inhibitory molecule of CD28 with age. Meanwhile, CD69—the early T cell
96
activation marker, CD25—the middle T cell activation marker and HLA-DR—the late T
cell activation marker also show age-related expression change [272, 273]. In concord
with those T cell changes, upon stimulation T cells from old donor show less proliferative
ability and have less IL-2 secretion. But old T cells also express more IFN-γ which
reflects the proinflammatory situation experienced by elderly.
Each of those age-related changes that being observed in T cell system carries a
piece of information that reflects at which stage of T cell development or in which aspect
of T cell function that ageing may have a deleterious effect on T cell. Conversely, if
any treatment or gene mutation can reverse one or some of the age-related changes, then
the possible target of this treatment or mutation can be easily narrowed to a small field.
The introduction of cbl-b knock-out (KO) mouse by Gu’s group [201] and
Penninger’s group [200] respectively not only show us sufficient evidence that Cbl-b is a
negative regulator of T cell signaling pathway, they also provide us a powerful tool to
directly study the role of Cbl-b in T cell senescence. The cbl-b KO mice generated by
Gu’s group [201] are normal in T cell development and immune cell repertoire. While
the peripheral T cells from cbl-b KO mouse are hyperactive in their function. cbl-b-/- T
cells can proliferate rapidly without costimulation from CD28 and secret high levels of
IL-2. Since both the CD28 expression and IL-2 production are what are missing in old
T cells, we have the hypothesis that cbl-b KO mice will continue to show a strong
proliferative ability and reverse some of the age-related changes observed in T cells.
Thus, in this chapter, features that already been proven to change in old wild type
immune system will be studied in cbl-b KO mouse to see if the old cbl-b KO mice can
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reverse those changes and evaluate the feasibility to use cbl-b KO mice as aging study
model.
4.3 MATERIALS AND METHODS
Materials
All antibodies were purchased from BD Pharmingen (La Jolla, CA) unless
otherwise noted in the text. All chemicals were reagent grade or better from Sigma-
Aldrich (St. Louis, MO).
Animals
C57BL/6 cbl-b knockout mice were obtained from Dr. Hua Gu [201]. Mice
were maintained on a 12 hour light/dark cycle and standard chow diet. All animal
procedures were approved by the University of Texas Animal Use and Care Committee.
T-lymphocyte isolation
Mice were sacrificed and spleens aseptically removed. Single splenic cell
suspensions were isolated by homogenization and filtering through a 25mm syringe filter.
Lymphocytes were isolated via differential migration following centrifugation in
Lymphocyte Separation Medium (Mediatech, Herndon, VA). T-lymphocytes were
isolated using negative selection Immulan columns (Biotecx, Houston, TX) per
manufacturer’s instructions as previously described [230]. Isolation by negative
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selection prevents perturbation of the T-lymphocyte’s receptor during the isolation
procedure, as occurs with isolation via positive selection. T-lymphocytes were counted
using the Cell-Dyn 900 Hematology Analyzer (Sequoia-Turner, Mountainview, CA).
T-lymphocyte proliferation
T-lymphocyte proliferation was determined by MTT cell proliferation assay
(ATCC, Manassas, VA). Briefly, 2x105 splenic T-lymphocytes (2x106 cells/ml) were
plated in each well and cultured at 37ºC with complete media in the presence of different
concentration of plate-bound anti-CD3 antibody for 48 hr. 10 µl MTT reagent was
added and continued incubating for 4 hr at 37ºC until purple precipitates were visible.
After that, 100 µl detergent reagent was added, plates were then left at room temperature
in the dark for 2 hr and absorbance was recorded at 550nm. T-lymphocytes for each
treatment were plated out in triplicate and average was used for data calculation.
T-lymphocyte stimulation
T-lymphocytes, 8x106 cells per petri dish (4x106 cells/ml) were stimulated at 37ºC
for 48 hours in pre-warmed complete culture media (RPMI 1640 supplemented with 10%
heat inactivated fetal bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 100




Splenic T-lymphocytes were stimulated as described before. 1 x 106 T-
lymphocytes were treated with 200 µl 1X RBC Lysis buffer (eBioscience, San Diego,
CA) for 2 minutes to lyse any remaining red blood cells that might interfere with
analysis. Lysis was ceased with the addition of 5ml PBS and centrifugation at 250 g for 5
min. Cell pellets were incubated with PE labeled anti-CD8 plus FITC labeled anti-CD4
antibody. Excess antibodies were removed by washing with PBS with 0.1% NaN3 and
cells were fixed in 0.5% paraformaldehyde in PBS. CD4, CD8 receptor expression on
T-lymphocyte subsets was analyzed using a BD FACScaliber flow cytometer and
CellQuest Pro software (BD Pharmingen, San Diego, CA).
To detect the proportion of T regulatory cells, cells were first stained with FITC
labeled anti-CD4 antibody as described before and washed with PBS with 0.1% NaN3.
Cells were resuspended with 1 ml of freshly prepared Fixation/Permeabilization working
solution (eBioscience, San Diego, CA) and incubated for 1 hour at 4ºC. After washing
with 2ml of 1x Permeabilization buffer twice, cells were resuspended in 50µl of 1x
Permeabilization buffer containing 5ml of PE labeled anti-Foxp3 antibody (eBioscience, 
San Diego, CA) and incubated for 1 hour at 4ºC. Excess antibodies were removed by
washing with 1x Permeabilization buffer (eBioscience, San Diego, CA). Cells were
fixed in 0.5% paraformaldehyde in PBS and analyzed as described before.
Statistical analysis
Data were analyzed by one-way ANOVA and statistical difference were
determined using Tukey’s multiple comparison test with GraphPad Prism software (San
Diego, CA). A p<0.05 was considered significantly different.
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4.4 RESULTS
T-lymphocyte proliferation in wild type and Cbl-b knock-out mice with age
In vitro T-lymphocyte function is usually measured by cell proliferation when
stimulated by soluble anti-CD3 antibody plus anti-CD28 antibody. As a negative
regulator of T cell activation, lack of Cbl-b expression would greatly improve T cell
proliferation even under less optimal stimulatory condition, like without the co-
stimulatory signal from CD28 [200, 201]. However, whether the Cbl-b knock-out (KO)
mice can keep the high proliferation rate when they are old are still unknown. Thus, we
first tested the proliferation ability of wild type (WT) and KO mice at the age of 6-8
month (young) and 18-20 month (old). The results are shown in Figure 4.1. In Figure
4.1A, the proliferation rate of young WT and KO T-lymphocytes are compared when
they are stimulated by different concentration of plate-bound anti-CD3 antibody. KO T-
lymphocytes showed significantly high proliferation activity at all concentration of anti-
CD3 antibody. Proliferation of KO T-lymphocytes is almost 2-fold higher than WT T-
lymphocytes when the concentrations of plate-bound anti-CD3 antibody are 2.5 µg/ml
(198% higher, p<0.05) and 5.0 mg/ml (192% higher, p<0.001). When the anti-CD3
concentration increased to 7.5 µg/ml and 10.0 µg/ml, the proliferation of T-lymphocyte
from both WT and KO mice increased accordingly, and the proliferation rate in KO mice
are 1.53-(7.5 µg/ml) and 1.57-fold(10.0 µg/ml) higher than the rate in WT mice. The
proliferation rate of old WT and KO mice T-lymphocytes are shown in Figure 4.1B, the
stronger T-lymphocyte proliferative ability were preserved in aged KO mice, but the
relative increasing fold in KO T-lymphocyte were decreased with age. At the
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concentration of 2.5 µg/ml, the T-lymphocyte proliferation in old KO mice was 38%
higher, and was 46% higher at the concentration of 5.0 µg/ml, 43% higher at 7.5 µg/ml,
and 50% higher at 10.0 µg/ml. The results of T-lymphocyte proliferation comparison
between young and old mice are shown in Figure 4.1C. At low stimulatory condition
(e.g. 2.5 µg/ml and 5.0 µg/ml of anti-CD3 antibody), the T-cell proliferation of old KO
mice is higher than that of young WT mice (94% higher at 2.5 µg/ml and 34% higher at
5.0 µg/ml). At high stimulation concentration (either 7.5 µg/ml or 10 µg/ml of anti-CD3
antibody), the T cell proliferation ability from old KO mice are similar to young WT
mice.
Features of immune system in Cbl-b knock-out mice with aging
Declines of T-lymphocyte function found in aging or other immune-related
diseases are associated with certain physiological changes, especially those organs
generating new T-lymphocytes and organs storing peripheral T-lymphocytes. Total
body weight, thymus weight, spleen weight are measured and the results are shown in
Figure 4.2. As shown in Figure 4.2A, the body weight of Cbl-b KO mice are almost the
same to WT mice in respective young and old age group. The effects of aging on body
weight are alike in both WT and Cbl-b KO mice that the weight increased about 7% with
age. The spleen weight of WT and Cbl-b KO mice at young and old age are shown in
Figure 4.2B. Spleen weight of young WT and young Cbl-b KO mice are similar too,
spleen size increased with age in both WT and Cbl-b KO mice. The spleen size in WT
mice almost doubled in WT mice (180% compare to the WT young mice) which is
significant, while in Cbl-b KO mice, weight of spleen increase just 24% in aged mice.
Figure 4.2C showed thymus weight change in WT and Cbl-b KO mice at young and old
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age. Thymus weight decreased with age in both WT and Cbl-b KO mice, but there was
no difference in thymus weight between the WT and KO mice in each age group.
CD4/CD8 homeostasis in Cbl-b knock-out mice
Since CD28-dependent down-regulation of Cbl-b in wild-type T-lymphocyte
happened only in CD4+ T cell subset, it would be expected that lack of Cbl-b expression
in both CD4+ and CD8+ T cells might show different effect on the proliferation of
individual subset and result in change of CD4/CD8 homeostasis. So the CD4+ and CD8+
T cells are stained and analyzed by flow cytometry in WT and Cbl-b KO mice at 4-6
month or 18-20 month, before and after 48 hr stimulation by plate-bound anti-CD3
antibody (10 mg/L). The results are shown in Figure 4.3. At young, unstimulated
group, the CD4/CD8 ratio in splenic T-lymphocyte shows no difference in WT and KO
mice, indicating that composition and activity of immune system at resting condition do
not change with Cbl-b deficiency. However, compared to their WT counterparts,
CD4/CD8 ratio is 40% lower in young Cbl-b KO T cells when they are stimulated.
Similar CD4/CD8 ratio drops were also observed in old Cbl-b KO T-lymphocytes, no
matter they were stimulated (45% lower) or not (27% lower).
Regulatory T cell population in Cbl-b knock-out mice
Regulatory T cell (Treg), a subgroup of T cells that express CD4 on cell surface
and Foxp3 intracellularly, shows suppressive function on proliferation of other T cell
[274, 275]. They play an important role in prevent autoimmune diseases,
transplantation tolerance, and cancer immunity [276]. The relative amount of Treg cells
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in Cbl-b KO mice comparing to the WT mice are tested. In most previous studies, Treg
cells were recognized by surface expression of CD4 and CD25 [277], however, more
recent studies show that transcription factor forkhead box P3 (Foxp3) is more essential
for the generation and activity of Treg cells [278, 279]. CD4
+CD25low/negFoxp3+ T cells
have suppressive function too [280]. Thus, we use the surface staining of CD4 and
intracellular staining of Foxp3 followed by flow cytometry analysis to identify the
existence of Treg cells in total splenic T cell pool and the results are shown in Figure 4.4.
Similar to what we observed in CD4/CD8 homeostasis data, in young, unstimulated
group, WT and Cbl-b KO mice contain same level of Treg cells, Treg cells are 4.1% of total
T cells in WT mice, and 4.3% of total T cells in Cbl-b KO mice. But when T cells were
stimulated, the Treg composition decreased in both WT and Cbl-b KO mice, and the Cbl-b
KO mice have less Treg cells after stimulation (1.78% in KO mice vs. 2.3% in WT mice).
The percentage of Treg cells increased with age in both groups (9.2% in WT mice and
6.4% in Cbl-b KO mice) and dropped after stimulation (3.5% in WT mice and 1.7% in
KO mice). In both situation, Cbl-b KO mice showed less Treg cells content.
4.5 DISCUSSION
Proliferation of T-lymphocyte is constantly greater in Cbl-b KO mice than in WT
mice at all anti-CD3 stimulatory condition if the two groups of mice are at the same age.
The hyper-activation of T-lymphocyte because of no Cbl-b expression is observed
throughout the life time of Cbl-b KO mice. However, the activity of T-lymphocyte in
Cbl-b KO mice decreases with age too, indicating the Cbl-b KO T-lymphocyte is also
under the aging regulation. Even though the proliferation rate of old KO T-lymphocyte
is significantly lower than young KO T-lymphocyte, it is still as active as young WT T-
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lymphocyte. This result suggests that the aging pace in Cbl-b KO mice is slowing
down, thus, immune system of aged Cbl-b KO mice would be more functional and be
able to fight more effectively against infection, autoimmune diseases and cancers.
Enlarged spleen, also called splenomegaly is a biomarker that associated with
aging too. It is commonly observed in old rats [281, 282] and is showed in mice with
premature aging diseases [283]. The cause of spleen enlargement can be either disease
related, like infection [284], liver problem [285], cancer [286], or life style related, for
example, diet induced obesity [287], or lack of exercise [288]. We also observed
significantly enlarged spleen in old WT group. In Cbl-b KO mouse, though the spleen
also enlarges with age, the extent is much less than its WT counterpart. Since the WT
and KO mice are using the same diet and not under exercise training, the difference of
spleen enlargement between WT and KO old mice may be a good indication of their
healthiness and immune function in aging. Thymus weight are dramatically decreased
with age in both WT and Cbl-b KO mice, and there is not much difference in thymus
weight when WT and Cbl-b KO mice are compared at the same age. This result is in
accordance with previous report that Cbl-b’s function is involved in peripheral T cell
activation, but not T cell development [289].
Lost of homeostasis in T cell population is another major feature responsible for
the dysregulation of T cell function in aging. Change of balance between peripheral
CD4 and CD8 T lymphocyte is often observed whenever physiological characters alter
due to disease or aging. Here, we found that CD4/CD8 ration is lower in Cbl-b KO
mice when splenic T cells are stimulated with anti-CD3 antibody. Skewing and
expansion of CD8+ T cell were characterized in B7 transgenic mice in a CD28-dependent
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way [290]. Since Cbl-b KO mice uncouple the T cell activation with requirement of
CD28 costimulation, the dropped CD4/CD8 ratio strongly suggests it is regulated by
CD28 pathway, which is activated in Cbl-b KO mice. The mechanism of CD28/CTLA-
4 regulation on CD4+ and CD8+ T cell homeostasis seems to be “CD28 signaling favors
CD8+ T cell expansion” [290] and CD4+ T cell is more sensitive to the negative regulation
of CTLA-4 engagement [291]. In other words, the activation threshold of CD8+ is lower
than CD4+ T cells; this is probably why in WT T-lymphocyte, CD28 co-stimulatory
signal only down-regulate Cbl-b expression in CD4+ T cell, thus CD4+ and CD8+ T cells
can achieve similar activation level under the same stimulation condition. The detailed
pathway is still unclear and need to be elucidated.
Regulatory T cell (Treg), previously characterized as CD4
+CD25+ T cells [277,
292], and now more specifically defined as CD4+Foxp3+ T cells [293], is a subgroup of T
cells with suppressive function. The roles of regulatory T cells include: to suppress
autoimmune diseases [277, 294, 295], to inhibit transplantation tolerance [277, 296], and
to prevent tumor immunity [297, 298]. The function of Treg cells are achieved by inhibit
the proliferation of both CD4+CD25- T cells [274] and CD8+ T cells [275]. The
correlation of higher Treg cell number with age and suppression of immune response in
aging have been approved [299-301].
Increased percentage of CD4+Foxp3+ Treg cells with age was observed in both WT
and Cbl-b KO mice, suggesting that Treg cells are important to the immunesenescence.
We also found that at most groups (except the young unstimulated group), Cbl-b KO
mice contain less CD4+Foxp3+ Treg cells than WT mice. Generation and peripheral
homeostasis of Treg cells are controlled by the integrated network of CD28/CTLA-4 and
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CD80/CD86 expression and interaction [302]. Both the CD28 and CTLA-4 signals
contribute to the peripheral maintenance of Treg cells. Absence of CD28 signal reduces
the number of Treg cells [302]. Function of CTLA-4 signal on Treg cells’ survival is
mediated by TGF-β. CTLA-4 increases TGF-β expression [303], and TGF-β can
upregulate Foxp3 expression [304-306]. In Cbl-b KO mice, T cells do not need the co-
stimulatory signal CD28 to achieve a high level of activation, however, T cells with no
Cbl-b expression also can not be regulated by the negative signal from CTLA-4
engagement. Thus, even though Cbl-b KO T cells do not require CD28 signal to
maintain the already existing Treg cell number, they are unable to induce Foxp3 expression
via CTLA-4/TGF-β pathway. The fact Cbl-b KO mice contains less Treg cells when
being stimulated or when being aged suggests that the role of CTLA-4/TGF-β is more
dominant in conversion of mature peripheral T cells into peripheral Treg cells.
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6-8 month mice

































































Figure 4.1 Influence of Cbl-b gene and aging on splenic T-lymphocyte proliferation.  
Splenic T-lymphocytes were isolated from young (6 mo, Y) and old (18 mo, O), wild 
type (WT) or Cbl-b knock-out (KO) mice as described in the Materials and Methods then 
activated with different concentration of plate-bound anti-CD3 antibodies for 48 hours 
and proliferation determined using the MTT dye uptake assay as described in the 
Materials and Methods.  Data are expressed as the absorbance at 550 nm.  Values are 
the mean ± SEM of 4 individual mice.  An ‘*’ indicates significantly different (p<0.05) 
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and ‘***’ indicates significantly different (P<0.001) when comparing the WT and KO 


























































Figure 4.2 Influence of Cbl-b gene and aging on mice body, spleen, and thymus weight.  
Spleen and thymus were removed from young (6 mo, Y) and old (18 mo, O), wild type 
(WT) or Cbl-b knock-out (KO) mice and weighed.  Values are the mean ± SEM of 8 
individual mice.  An ‘*’ indicates significantly different (p<0.05), ‘**’ indicates 
significantly different (p<0.01) and ‘***’ indicates significantly different (P<0.001) when 
comparing the young and old group.   
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Figure 4.3 CD4/CD8 ratios in Cbl-b knock-out mice
Figure 4.3 Decreased CD4/CD8 ratios in stimulated and aged Cbl-b knock-out mice.  
Splenic T-lymphocytes were isolated from young (6 mo, Y) and old (18 mo, O), wild 
type (WT) or Cbl-b knock-out (KO) mice, then activated with 10mg/L of plate-bound 
anti-CD3 antibodies for 48 hours.  Cells were stained and analyzed via flow cytometry 
as described in the Materials and Methods.  Values are the mean ± SEM of 6 individual 
mice.   
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Figure 4.4 Regulatory T cells in Cbl-b knock-out mice
Figure 4.4 Decreased regulatory T cell percent in stimulated and aged Cbl-b knock-out 
mice.  Splenic T-lymphocytes were isolated from young (6 mo, Y) and old (18 mo, O), 
wild type (WT) or Cbl-b knock-out (KO) mice, then activated with 10mg/L of plate-
bound anti-CD3 antibodies for 48 hours.  Cells were stained and analyzed via flow 
cytometry as described in the Materials and Methods.  Values are the mean ± SEM of 6 
individual mice.   
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Chapter 5: Conclusions
Prompt and accurate immune response is crucial for persons at all ages to protect
themselves from infection caused by microbes and viruses. However, one of the biggest
concerns associated with the health care for elderly is the dysfunction of immune system,
either inadequate proliferation reaction and cytokine secretion in lymphocytes, or
unnecessarily production of auto antibodies. For decades, studies have been focused on
alteration of intracellular signaling transduction that leads to abnormal gene transcription.
A key regulatory process in signaling pathway is phosphorylation, and one of the
important roles of protein phosphorylation is to relay and amplify the stimulatory signals
from the original receptor to the ultimate effecter. Changes of protein phosphorylation
in aging process had been well studied, while there are still many questions about aging-
related alteration in signaling transduction being unaddressed.
Though relatively new to the signaling transduction network, ubiquitin is
receiving more and more attention. This is because ubiqutin has the same major
features as phosphorylation, thus ubiqutin is considered as another essential protein
modification in signaling transduction. Also, ubiquitination usually give negative
regulation to involved signaling transductor, which may complement with the positive
regulation provided by phosphorylation. So, a better understanding of ubiqutin and its
regulation in aging process is urgently required.
This study has been focused on role of Cbl-b, an E3 ubiqutin ligase, in
dysregulation of T cell function in aging. First, the expression and change of Cbl-b in
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response to stimulatory signals were tested solely in young rat splenic T-lymphocytes,
and the mechanism of Cbl-b’s reaction to the signals were studied too. We found that
protein level of Cbl-b will decrease when T-lymphocytes are stimulated with both anti-
CD3 and anti-CD28 antibodies. Thus, all the effecters downstream of Cbl-b will be
activated/upregulated since the negative regulatory signal exerted by Cbl-b is removed.
The down-regulation of Cbl-b upon stimulation is similar to opening a dam (remove Cbl-
b) and let water (stimulatory signal) flow through to keep the whole water system (cell
function) manageable (cell proliferation and cytokine secretion). The decrease of Cbl-b
disappears if only CD3 receptor being stimulated while the extent of Cbl-b down-
regulation increases if only CD28 receptors are activated. The differential reaction of
Cbl-b toward CD3 and CD28 stimulation suggests that these two signals play different
roles in regulating Cbl-b. Only signals from stimulated CD28 receptor can regulate the
protein expression of Cbl-b and control Cbl-b’s function quantatively. As for the CD3
signal, since addition of CD3 antibody to CD28 will slow down the pace of Cbl-b being
decreased by CD28 signal, CD3 signal also plays an important role in regulating Cbl-b’s
function, via a mechanism other than expression change.
The detailed mechanism of down-regulation of Cbl-b by CD28 signal was studied
in this project. According to the previous research in transfected T cell lines, our
research have been focused on another E3 ubiqutin ligase Nedd4, Itch and a
transcriptional regulator Egr2/3. Experimental data showed that Nedd4, but not Itch and
Egr family proteins are directly responsible for the degradation of Cbl-b. Whenever
there is a CD28 stimulatory signal, both the transcription and translation of Nedd4 will
increase. The intracellular location of total Nedd4 change with CD28 stimulation too.
Nedd4 moves to be associated with Cbl-b, adds ubiquitin to Cbl-b and sends the Ub-
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labelled Cbl-b to proteasome for degradation. Although we still lack direct evidence
(such as siRNA of Nedd4), while together with the fact that transcription of Cbl-b does
not change upon either CD3 or CD28 stimulation, we made the conclusion that the
protein level change of Cbl-b is controlled directly by Nedd4 but not Egr family. The
mechanism of regulation on Nedd4 mRNA expression is still unknown. Whether Egr
family play a role in controlling Nedd4 transcription and thus indirectly regulate Cbl-b
protein expression are still under study. The experimental result on this topic will
complete our study of detailed mechanism of Cbl-b expression change in young splenic T
lymphocytes upon different stimulation.
In old splenic T-lymphocytes, a strong correlation ship was observed between the
decreased cell proliferation and anti-down-regulation of Cbl-b protein when cells are
stimulated under the same condition as they were stimulated in young splenic T cells.
Since in old T cells, Cbl-b maintained its function of binding with and ubiquitinizing
PI3K, the sustained high protein level of Cbl-b blocked stimulatory signals being
transferred from receptors to downstream effecters, and consequently impeded cell
proliferation and cytokine secretion with age. We have tested factors that involved in
controlling Cbl-b expression, including CD4/CD8 homeostasis, CD28 and CTLA-4
expression, binding with Nedd4, and ubiquitination of Cbl-b. They all appeared to be
normal in aged T lymphocytes. The main reason that causes the inability of down-
regulating Cbl-b in aged T cells is insufficient proteasome activity.
Since only an association relationship has been established between the higher
Cbl-b expression and lower proliferation rate in old T-lymphocytes, we want to further
determine the cause-effect relationship between Cbl-b and cell proliferation in aging.
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Cbl-b KO mice showed a much stronger proliferation reaction under CD3 only
stimulation. Compare to WT T-lymphocytes, the relative higher proliferative ability of
Cbl-b KO T-lymphocytes remained even when they were at old age and the proliferative
rate of old Cbl-b KO T-lymphocytes were comparable to young, wild-type T-
lymphocytes. Regarding other features of immune system, Cbl-b KO mice also show
other advantages, such as less enlargement in spleen, less suppressive T regulatory cells,
and less skew in CD4/CD8 homeostasis. The aging process is slowed down but not
completely stopped in Cbl-b KO mice.
The study about regulation put on Cbl-b’s expression under different stimulatory
condition and role of Cbl-b in immunesenescence indicate that Cbl-b play an important
role in peripheral T cell function. Accurate manipulation on Cbl-b protein expression
will lead to a better understanding and control of many diseases, and consequently
improve the overall life quality in aged population.
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